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Microbial fermentation has been a mean for humans to convert raw materials 
into refined food for thousands of years; bread, wine and beer are the most well-
known examples. In recent years, with the development of genetic engineering, 
microorganisms have been modified for the production of non-native substances 
with the aim of reducing costs and increasing the availability of compounds such as 
human insulin, plant derived drugs or biofuel. Genetic engineering has then become 
the basis of two main biological fields: synthetic biology and metabolic engineering. 
While synthetic biology aims at the complete engineering of entire cells via, 
among other tools, the creation of artificial genomes, metabolic engineering modifies 
the microbial native pathways to improve production of specific compounds. 
When synthetic biology and metabolic engineering meet, the result is a 
microorganism whose pathways have been tuned towards the production of one or 
more valuable heterologous substances. Before such a proof of principle organism 
can become a proper “platform organism” or “cell factory”, it has to meet industrial 
standards of yield, titer and productivity.  
The process to obtain a strain that is optimized for the production of a single 
compound or for a class of compounds in general requires a development time 
between three and six years with a minimum of one hundred people working on this 
objective every year. In order to reduce the time invested in research, companies 
have been focusing on just a few already well-established industrial microorganisms. 
Depending on the structure of the compounds, different microorganisms have been 
chosen. For example, Corynebacterium species have been used extensively for the 
production of amino acids, while different strains of Saccharomyces cerevisiae have 
been engineered to maximize the yields of biofuels, food ingredients or 
pharmaceuticals. The advantages of using model organisms for industrial purposes 
include available genome databases, the existence of single or multiple gene mutants, 
extensively studied metabolic pathways and molecular engineering tools optimized 
for fast genetic transformation and functional screening. Nevertheless, it is important 
to consider that the biodiversity in nature can provide numerous organisms which 
have not been fully characterized, yet, but that might provide further advantages over 
the common laboratory and industrial strains.  
A microorganism that is already capable of producing compounds similar to 
the molecular targets or has a high flux of the precursors involved in the synthesis of 






a specific chemical would be a good candidate when searching for alternatives to the 
already well known microbes.  
In order to identify a potential platform organism for the production of 
terpenoids and, in particular sesquiterpenes, alternative to S. cerevisiae, the 
potential of the basidiomycetous yeast Xanthophyllomyces dendrorhous was 
elucidated in this thesis. 
The importance of terpenes, their functions, their secondary metabolic 
pathways and research on the metabolic engineering of microorganism for the 
production of expensive terpene based drugs with limited availability are reviewed in 
Chapter 2. In this chapter, X. dendrorhous is introduced and an update on the 
ongoing research on this yeast is provided. 
 
Chapter 3 demonstrates the production of the first non-native terpene, 
pentalenene, in X. dendrorhous. The transformation of the yeast is obtained by the 
concurrent inactivation by insertion of two genes involved in the carotenoid pathway 
toward the production of astaxanthin. 
 
In Chapter 4, the synthase gene from Coprinus cinereus, Cop6, is 
transferred to S. cerevisiae and X. dendrorhous for a comparison in -cuprenene 
production between the two organisms. The putative germacrene synthase gene from 
C. cinereus, Cop4, is used to demonstrate the differences in terpene production 
between the two yeasts. Furthermore, the transformation of X. dendrorhous with a 
vector containing Cop6 and the two cytochromes COX1 and COX2 results in a mutant 
strain able to express the three genes and produce the compound lagopodin A, as 
explained in Chapter 5. 
 
The possibility of expressing the terpene cyclase amorphadiene synthase 
(ADS) in different cell compartments is expanded in Chapter 6. The targeting 
sequences for the mitochondria and for the peroxisomes in S. cerevisiae are fused to 
the ADS and to the green fluorescent protein (GFP) to demonstrate the transferring 
of the proteins to the right compartments and to compare the amorphadiene 
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Terpenoids and their properties 
With more than 25,000 identified structures from plants, microorganisms, 
insects and marine organisms, terpenoids are one of the largest class of natural 
compounds [1]. Terpenoids serve many, very diverse functions in the natural world ; 
their roles span from membrane fluidity and hormone signaling (sterols) [2], 
photosynthesis in plants and antioxidant agents in fungi (carotenoids) [3, 4], to 
electron transport or antimicrobial compounds (quinones) [5, 6] and protein 
glycosylation (dolichol) [7]. 
Food and pharmaceutical industries have already commercialized several 
compounds with terpene skeletons possessing interesting properties. Some good 
examples are menthol (Fig. 1A) as flavoring agent [8], artemisinin (Fig. 1B) as 
antimalarial drug [9] and paclitaxel (Taxol) (Fig. 1C) showing antineoplastic 
properties [10]. 
Furthermore, enzymes in the two biosynthetic routes, the mevalonate (MVA) 
and the 2C-methyl-D-erythrotol-4-phosphate (MEP) pathway, used by several 
organisms to produce terpenes have been targeted for a wide range of medicinal 
purposes. For example, statins, the cholesterol lowering drugs, act by inhibiting the 
first enzyme in the MVA pathway, hydroxy methylglutaryl CoA reductase (HMGR) 
and thus depleting cells of downstream terpenoids, including farnesyl diphosphate 
(FPP). FPP is a key intermediate in the synthesis of cholesterol and its reduced 
production results in a decreased de novo cholesterol synthesis [11]. While statins 
inhibit the HMGR from the MVA pathway, the second enzyme of the MEP pathway, 
1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), which converts 1-deoxy-D-
xylulose-5-phosphate (DXP) into the branched compound MEP [12], is the molecular 
target for fosmidomycin. The MEP pathway enzymes are highly conserved but show 
no homology to mammalian proteins [13]. This implies that the use of such a specific 
inhibitor would result in novel antimicrobial drugs with broad spectrum activity and 
little toxicity to humans.  
 
 























Figure 1. (A) menthol; (B) artemisinin and (C) paclitaxel 
 
 
Terpene compounds like limonene, menthol and carotenoids are available in 
discrete quantities in nature and can be produced and purified simply. But 
terpenoids like artemisinin and paclitaxel are rare and have low abundance, causing 
supply problems. Metabolic engineering is a new concept in molecular biology and 
considered as new avenue for the production of rare and high-cost natural products. 
In the artemisinin and paclitaxel biosynthesis pathways most enzymes are known, 
allowing the introduction of the complete primary and secondary pathway in 
heterologous hosts possible. The main idea is the complete transfer of a plant 
terpenoid pathway to a microorganism to optimize the biosynthetic production rate 
by fermentation of the genetically engineered microorganisms. However, the targeted 
bacterial and fungal pathways are regulated through complex networks. 












mechanisms are unknown. In this chapter the challenges and promises of recent 
developments in terpenoid pathway engineering will be discussed. 
Biosynthesis of terpenoids in several organisms 
Nature has developed two biosynthetic pathways for the production of the 
terpenoid backbones, namely MVA and MEP. The MVA pathway (Fig. 2) has been 
described by the Nobel Prize winners Bloch and Lynen, who elucidated the 
cholesterol pathway [14]. For almost 40 years it was thought that all isoprenes 
descended from the MVA pathway, although studies indicated that not all of the 
produced terpenoid structures could be explained solely by the MVA pathway. In 
1993, an alternative pathway for isopentenyl diphosphate (IPP) biosynthesis (Fig. 3) 
was reported in bacteria, through intensive analysis of 13C labeling in hopanoid 
production by the microorganisms studied [15]. Soon after the publications 
describing the alternative pathway, others reported the same pathway in algae, 
diatoms, and protozoa [16, 17]. The nomenclature for the alternative pathway was 
confusing as various names had been used in literature, like DOXP-, DXP-, MEP-, 
Rohmer- or non-mevalonate pathway. Only recently the pathway was officially 
named the “MEP pathway”, according to the first official precursor in the 
biosynthetic route in Escherichia coli [18]. 
Both pathways produce IPP; however, delivery of precursors depends on 
alternative metabolic routes. The MVA pathway is fed by the precursor acetyl-CoA 
obtained in the citrate cycle. The MEP pathway is, instead, mainly fed by D-
glyceraldehyde 3-phosphate, produced via the pentose phosphate pathway, and 
pyruvate, present in several metabolic routes, including the citrate cycle and 
glycolysis [19]. However, in photosynthetic organisms and in anaerobic conditions, 
the MEP pathway is mainly fed through production of the same precursors by the 
Calvin cycle [20, 21]. 
Higher plants possess both pathways, while prokaryotes, with some 
exceptions [22], have the MEP pathway, and other eukaryotes may use either the 
MEP or MVA pathway. In addition, higher plants have separated the two pathways in 
different compartments. The MVA pathway is localized in the cytosol, while the MEP 
pathway is separated in plastids. The coexistence of both pathways in higher plants 
and the intracellular trafficking of precursors makes higher plants unique compared 
to prokaryotes and the eukaryotes that have only one of two biosynthetic routes.  




























Figure 2. The MVA pathway.  
1. HMG-CoA synthase (HMGS);  
2. HMG-CoA reductase (HMGR);  
3. mevalonate kinase;  
4. phosphomevalonate kinase;  































Figure 3. The MEP pathway. 6. 1-deoxy-D-xylulose-5-phosphate synthase; 7. 1-deoxy-D-
xylulose-5-phosphate reductoisomerase (DXR); 8. 4-diphosphocytidyl-2-C-methyl-D-
erythritol synthase; 9. 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase; 10. 2-C-methyl-D-
erythritol-2,4-cyclodiphosphate synthase; 11. 2-C-methyl-D-erythritol-2,4-cyclodiphosphate 
reductase; 12. 1-hydroxy-2-methyl-2-butenyl-4-diphosphate reductase (HDR). 
 
The interchange of metabolites, named “cross talking,” occurs in varying 
degrees between species and depends on physiological conditions [23-27]. The 






regulatory system controlling this cross talking is not yet fully understood [28] and 
elucidating this system remains a major challenge in biochemistry and metabolic 
engineering. 
Various terpene synthases are known to convert the terpenoid backbone into 
pathway-specific structures; however, some are less specific and can produce more 
than one structure [29]. During the enzymatic modification of common terpenoid 
backbones (Fig. 4), like geranyl diphosphate (GPP), FPP or geranyl-geranyl 
diphosphate (GGPP) a divalent metal, generally magnesium, is used to stabilize the 
diphosphate group. After this transformation, the pyrophosphate is lost and more 
species-specific enzymes (e.g., cytochromes) are used by the organisms to create the 










(DMAPP) to GPP, 




14. GPP synthase 
(GPPS); 
15. FPP synthase 
(FPPS); 
16. GGPP synthase 
(GGPPS) 
Sesquiterpenoids and diterpenoids often possess macrocyclic rings as 
exemplified in artemisinin, paclitaxel, and ginkgolide. The enzymes responsible for 
the ring closing step are the terpenoid cyclases. A comparison between terpenoid 









[32, 33]. The major difference between terpenoid synthases derived from plants and 
those produced by microorganisms is the presence of an N-terminal sequence in 
plant enzymes. This N-terminal sequence is similar to a glucosyl hydrolase [33], and 
is crucial for the enzyme activity [34], although the specific function remains 
unknown. The diversity of the secondary terpenoids is caused by promiscuity, 
mutations, and various enzymes acting downstream on the terpene skeleton and may 
explain chemotypes within a family or species as it is known for Mentha x piperita or 
Thymus vulgaris. This variation can be used for the selection of highly producing 
species for commercial medicinal plant cultivation, commercial microbiological 
fermentation and more sophisticated strategies in metabolic engineering.  
Metabolic fluxes can differ among families, species and even within a 
multicellular organism. An example is the production of astaxanthin by various 
hosts. Several studies were performed on the production capacities of yeasts, plants, 
and microalgae. These studies show that wild-type production levels of astaxanthin 
differ dramatically between hosts. Chlorella zofingiensis (a microalga) produces 
about 0.1% astaxanthin of the dry weight, Nicotiana tabacum around 0.24% [35], 
Xanthophyllomyces dendrorhous between 0.4% and 2.5% [36], and the highest 
production in a wild-type organism of asthaxanthin is obtained by the microalga 
Haematococcus pluvialis with production levels of around 3% of dry weight [37, 38]. 
Next to accumulation levels, the produced enantiomer is also different in various 
species. For instance, in X. dendrorhous the all-trans isomer is mainly produced 
[39], where H. pluvialis produces mainly the all-cis isomer [40]. 
 
Metabolic engineering of the terpenoid pathway 
Metabolic engineering is considered as one of the major concepts in 
biotechnology. At the moment, genetic engineering allows the transfer of a 
biosynthetic pathway to any selected host. The isoprenoid pathway is an example of 
how biosynthetic-relevant genes can be reassembled from biological sources (e.g., 
plants, bacteria and fungi) into a heterologous microorganism. Engineering of plant 
terpenoids into microbial hosts has focused mainly on isoprenoid-derived 
compounds such as carotenoids [41], artemisinin [42], and paclitaxel [43]. The 
production of carotenoids and artemisinin demonstrates that complex natural 
products can be produced by microbial fermentation with yields approaching 






commercial viability. Development of a microbial production platform for the 
biosynthesis of complex terpenoids offers large-scale and cost-effective industrial 
production via fermentation, which is independent from climate (too dry, too wet) 
and cultivation risks (inefficient pest control, weeds competing for food, bad soil 
conditions). Well-characterized and genetically easy to manipulate heterologous 
hosts like E. coli and S. cerevisiae allow specific engineering of biosynthetic pathways 
for increased yields and the generation of novel compounds. Although extensive 
engineering is frequently required to successfully reconstitute biosynthetic pathways 
in these hosts, the potential to easily manipulate the biosynthesis is a significant 
advantage when compared to engineering in poorly characterized host strains or 
non-microbial systems.  
Engineering the primary metabolism 
The first enzyme committed to the MEP pathway (6) is 1-deoxy-D-xylulose-
5-phosphate synthase (DXS). This enzyme is documented to be involved in the rate-
limiting step in the MEP pathway [44] and, as a consequence, it is often subject to 
overexpression with the goal to increase production of GPP and, in extension, 
monoterpenes. A recent example of DXS overexpression in Lavandula latifolia 
resulted in a 4.6-fold increase of essential oils in leaves and a 1.74-fold increase in 
flowers compared with the control plant [45]. However, Botella-Pavia and Besumbes 
proved that in transgenic Arabidopsis thaliana grown under light conditions 
hydroxymethylbutenyl diphosphate reductase (HDR) (12), a late enzyme in the MEP 
pathway that simultaneously synthesizes IPP and DMAPP, functions as the rate-
determining enzyme, rather than DXS. In their experimental setup with recombinant 
A. thaliana expressing taxadiene synthase (TXS), DXS was overexpressed, and 
taxadiene production increased six times compared to the plant line solely expressing 
the taxadiene synthase. Furthermore, constitutive coexpression of TXS and HDR 
resulted in a 13 times higher production of taxadiene (TXD) [46, 47]. These studies 
clearly indicate that more knowledge on pathway regulation is essential for a better 
understanding of the metabolic engineering and flux improvement. 
A well-known regulation mechanism in the MVA biosynthetic pathway acts 
on the enzyme HMGR (2). This enzyme converts the substrate HMG-CoA to 









Several groups have successfully overexpressed this gene to increase the production 
of downstream isoprenoids. The enzyme is inhibited by phosphorylation as a control 
mechanism and is stimulated by accumulation of downstream sterols. Accumulation 
of phytosterols in seeds was observed in transgenic tobacco plants expressing a 
mutated form of HMGR from Arabidopsis thaliana. The serine in the recognition site 
for the HMGR-kinase was replaced by an alanine, causing insensitivity to the 
phosphorylation and thus reduced degradation. Although accumulation of 
phytosterols was only observed in the seeds and not in the leaves, the authors did not 
describe the presence of other isoprene derivatives, whose concentration could be 
elevated by the increased presence of mevalonic acid [49]. Another example of 
HMGR modification is the truncation of the N-terminal membrane anchor domain 
and exclusive expression of the catalytic C-terminal domain of the protein. The 
truncated form of HMGR (tHMGR) increased the flux through the MVA pathway as 
it is unresponsive to negative feedback by FPP [50, 51]. 
Strategies to maximize IPP production are more complex than single gene 
expression or inclusion of various endogenous enzymes from the MVA or MEP 
pathway. Currently employed strategies include the expression of multiple 
heterologous genes or even of complete heterologous pathways [52-54]. One 
approach to introduce the MVA pathway from S. cerevisiae into E. coli, led to an 
elevated production (112.2 mg/l) of amorphadiene (AD). This is a 6.5 fold increase to 
when only amorphadiene synthase (ADS) was expressed in E. coli [55]. While 
expressing heterologous genes or pathways for overproduction of isoprenoids is 
highly desirable, a serious risk is host-specific down-regulation of the heterologous 
biosynthetic genes. For maximal production the engineered pathway was required to 
be tuned suboptimal in several cases. Pitera and colleagues described a good example 
in which the heterologous MVA pathway engineered in E. coli, which normally 
harbors exclusively the MEP pathway (Fig. 3), leads to accumulation of enzymatic 
products that induce growth inhibition or become toxic to the host. Only by fine-
tuning of the gene expression these bottlenecks of isoprenoid production became 
acceptable and relieved the growth inhibition. The tuning was accomplished by 
monitoring the specific metabolic profiles of well-growing and growth-limited 
mutants. By titration of gene expression and analysis of metabolite production, 
HMG-CoA accumulation proved to be one of the reasons of growth inhibition. After 
introduction of tHMGR, the rate of biosynthesis was increased, and growth was 
restored by approaching the growth rate of the wild type [56]. 






Bottlenecks within pathways have an important role, as they serve as control 
points within a native organism to regulate resource utilization and production of 
metabolites. Metabolic engineering strives to elevate these bottlenecks by adapting 
expression levels of native or heterologous proteins and inherently increase 
production rates and levels of metabolites. A way to empirically identify the optimal 
tuning of genes and, hence, eliminate bottlenecks in a pathway involves the creation 
of a library from the intergenic regions containing various mRNA secondary 
structures, RNase cleavage sites, and ribosomal binding site sequestering sequences 
[57]. Another parameter that has to be considered is the promoter, which can have a 
significant influence on product yield, as described in a case of chromosomal 
replacement of endogenous promoter with the exogenous strong bacteriophage T5 
promoter in E. coli [58]. 
Parallel usage of transcriptomics, proteomics and metabolomics becomes 
more often the chosen strategy to elucidate the circuit before engineering [59-61]. 
After engineering a pathway, it is desirable to analyze the metabolic profile to be able 
to compare before–after situations and detect effects on the pathway originating 
from more distant networks. The ultimate goal is to be able to predict which steps 
need to be engineered to maximize the metabolic flux in a desired pathway. This can 
be done by comprehensive 13C-glucose labeling studies in which the distribution of 
the heavy atom among the metabolites is calculated based on the known 
biochemistry of the participating pathways and, at the same time, taking into account 
general cofactors such as ATP, NADH, and NADPH [62]. Biological sensors represent 
a new technique that is used in addition to standard analytical methods such as 
NMR, GCMS and HPLC, to detect higher carbon flux through a pathway. An example 
of a biosensor system is based on a strain where the MEP pathway has been 
permanently disrupted by deleting an early gene in the pathway. Gene disruption 
makes the cell auxotrophic for isoprenoids due to lack of production of IPP and 
DMAPP. As a consequence, this strain can produce isoprenoid building blocks 
exclusively via an engineered partial MVA pathway containing the enzymes 
downstream of HMGR or when MVA is supplemented to the media. This strain was 
further engineered to express green fluorescent protein (GFP) constitutively, for real-
time growth rate detection. Furthermore, the auxotrophic strain was co-cultivated 
with a second strain producing mevalonate allowing survival of the first strain. The 
growing bacteria gave a fluorescent signal, which was correlated to the levels of 









The use of auxotrophic strains also helps in the struggle for plasmid 
stabilization in microorganisms like E. coli. An example is the cloning of a 
heterologous MVA pathway in an E. coli knockout where the last step responsible for 
IPP production had been deleted from the genome and rescued by a similar gene on 
the plasmid. By using an auxotrophic strain and the plasmid to rescue the IPP 
production, higher plasmid stability was established [64]. 
Predictions on metabolic fluxes have successfully been performed to identify 
target genes to be knocked out for an increased lycopene production in E. coli. This 
research has led to the construction of a knockout variant that produces 40% more 
lycopene compared to the parental strain [65]. A recent approach to obtain maximum 
production levels did not only rely on a single knockout or overexpression of single 
genes, but instead on a multidimensional target search combining knockout and 
overexpression targets [66]. A multidimensional search was performed combining 
several one-dimensional search programs. Hereby, it became possible to screen in 
silico combinations of knockouts and overexpression patterns that would not have 
been detected using a single one-dimensional search. Based on initial selection of 
mutant candidates from in silico predictions, 40 mutants were constructed and 
screened for optimized carotenoids production. Grown in a minimal medium with 
glucose, an identified superior single strain produced 16 mg of carotenoids per gram 
of cells in 24 hours. Recombinant carotenoids production is a comparatively simple 
system for the validation of in silico prediction models as the products can be 
detected easily by spectroscopy due to their typical yellow to red color [67]. 
Out of simplicity reasons, most engineering efforts have focused on the 
primary pathway to optimize carotenoid production and have neglected parallel or 
distant pathways competing for precursors and cofactors. System biology opens the 
possibility to handle the interactions between biological networks at transcriptomics 
and at metabolomics levels. An example is the work of Papon and colleagues which 
looked outside the MVA and MEP biosynthetic pathways for non-direct regulation of 
IPP production. Here, supplementation of cytokinin and ethylene had a positive 
effect on the expression level of three genes from the MEP pathway in Catharanthus 
roseus cell suspensions [68]. In yeast, redirection of the carbon flux from competing 
pathways, such as sterols, into the desired pathway for the production of terpenoids 
has proven to be successful. By downregulating ERG9, a squalene synthase in S. 
cerevisiae, the production of the sesquiterpenoid AD was increased 5-fold when 
compared to a strain in which only ADS was expressed [69]. 






A novel strategy increases the pathway competition, rather than reducing it. 
The main idea is to overexpress an enzyme situated at a branching point in the 
biosynthetic network. One interesting branching enzyme in yeast is the acetaldehyde 
dehydrogenase competing for cytosolic acetaldehyde, which compound if otherwise 
transported and used in the mitochondria. With additional overexpression of a 
heterologous cytosolic acetyl-CoA synthase and the ADS a metabolic sink was created 
to drive the carbon flux into the MVA pathway and produce AD [70]. 
High yields of carotenoids in cauliflower (Brassica oleracea L. var. botrytis) 
were accomplished when a metabolic sink was combined with overexpression of 
carotenoid biosynthetic enzymes [71]. In plants, carotenoids are synthesized in the 
membranes of the plastids and accumulated in the chromoplasts that can store 
carotenoids with tremendous efficacy and act as a metabolic sink preventing possible 
negative feedback in the biosynthetic pathway. By overexpression in B. oleracea of 
Or, a gene involved in differentiation of plastids into chromoplasts, a 5 times increase 
in concentration of -carotene was obtained in a heterozygous mutant and an 8 times 
increase in a homozygous mutant. A remarkable result was that Or did not affect the 
expression levels of carotenoid or MEP pathway biosynthetic genes [72, 73]. 
However, when making use of organelles as production sites, it is important to 
consider the adverse effect of depletion of common metabolites that cannot be 
transported across membranes. As an example, depletion of acetyl-CoA in tobacco 
mitochondria, caused by the expression of an acetyl-CoA hydrolase, resulted in a 
growth-affected phenotype [74]. 
 
Engineering the secondary metabolism: artemisinin, paclitaxel and 
astaxanthin 
In contrast to the primary metabolism, no common biological components 
exist which would be present in all different secondary pathways. Secondary 
metabolite routes are per definition species specific, and therefore a high diversity in 
molecular structures between organisms in the terpenoid biosynthesis is to be 
expected [75]. Artemisinin is an excellent example since Artemisia annua produces 
low amounts of artemisinin, while its relatives Artemisia absinthium [76] and 
Artemisia afra [77] produce no artemisinin at all. The properties of many terpenoids 









complex or lack an identification of enzymes; for this reason, three case studies will 
be discussed: artemisinin, paclitaxel, and astaxanthin. 
Artemisinin (Fig. 1A) is a sesquiterpenoid lactone endoperoxide extracted 
from A. annua L. (Asteraceae; known also as “sweet wormwood”). The activity of 
artemisinin against malaria parasite P. falciparum has been well established. 
Artemisinin has been proven to act by selective inhibition of the 
sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA). The same study shows 
that artemisinin induces a change in the membranous structures in the cytoplasm of 
parasites inside erythrocytes [9]. Examples of derivatives of artemisinin include 
artemether and artemisone, which are on the market or currently under development 
[78]. 
The low production yield of artemisinin from A. annua (0.01–1% of dry 
weight) has led to difficulties in managing the demand while offering an acceptable 
price for most patients [79, 80]. The wish to improve the overall supply of 
artemisinin at reduced market price has encouraged interest in molecular biology 
and biochemistry of artemisinin biosynthesis (Fig. 5) [31, 81-85]. A recent study 
demonstrates that both the cytosolic MVA pathway and the plastidic MEP pathway 
might be involved in the production of IPP for artemisinin biosynthesis [86]. The 
biosynthesis starts with the cyclization of FPP to AD by ADS (17) [87]. Subsequent 
enzymatic steps can be executed in different orders. The primary conversion scheme 
in planta for production of artemisinin includes the oxidation of AD to artemisinic 
alcohol followed by a further oxidation at C12 from alcohol to aldehyde by the 
cytochrome P450 CYP71AV1 (18). In the subsequent step, the carbon double bond at 
C11, 13 is reduced giving dihydroartemisinic aldehyde by artemisinic aldehyde 
reductase Dbr2 (19), then dihydroartemisinic aldehyde is transformed into 
dihydroartemisinic acid by the CYP71AV1. The formation of the 1,2,4-trioxane moiety 
is poorly understood at the moment and is suggested to occur in a non-enzymatic 
manner (Ro et al. 2006; Covello et al. 2007; Rydén and Kayser 2007). Identification 
of these last unknown enzymes is essential for the production of artemisinin in 
heterologous systems. The applicability of heterologous expression was proven for 
the first time by the expression of the genes ADS and cytochrome P450 CYP71AV1 in 
yeast. The transgenic S. cerevisiae strain produces more artemisinic acid in contrast 
to relative plant biomass (4.5% dry weight in yeast compared to 1.9% artemisinic 
acid, and 0.16% artemisinin in A. annua) and in a shorter time (4–5 days for yeast 






versus several months for A. annua [84]. When these two enzymes were expressed in 
yeast together with Dbr2, dihydroartemisinic acid was produced at a level of 15.7 
(±1.4)-mg/l culture and the related artemisinic acid was produced at levels of 11.8 
mg/l [88]. The production of artemisinic acid was reduced compared to a mutant in 
which the artemisinic aldehyde reductase was not present (29.4 mg/l). In the latter 
mutant instead dihydroartemisinic acid was produced. The synthesis of 
dihydroartemisinic acid is preferred because it is converted towards artemisinin 
straightforward and with a reduced cost. Westfall and colleagues further modified S. 
cerevisiae to yield amorphadiene at a concentration of 40 g/L. In spite of the major 
increase in amorphadiene production the production of artemisinic acid remained 
similar at 1.8 g/L [89]. 
Today, artemisinin production has also been improved by means of genetic 
transformation of A. annua plants [80]. Cotton FPP synthase was transferred to A. 
annua, and the transgenic plant showed an artemisinin production of 8–10 mg/g dry 
weight, which is 2 or 3 times higher than the wild type plants [90]. In addition, the 
overexpression of the IPP transferase gene in A. annua increased artemisinin content 
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Paclitaxel is a well-known example of a clinically important natural product 
with dramatic problems of supply. Paclitaxel is isolated from the bark of the Pacific 
yew (Taxus brevifolia), which is a rare and slowly growing tree. In addition, the 
amount of the active constituent produced in the tree is about 1 mg per 750 kg of bark 
[92], and its harvest is destructive for the tree itself. An alternative production system 
is the Taxus cell culture, which allows increased paclitaxel production after methyl 
jasmonate induction [93]. Furthermore, fungi including endophytes produce taxanes, 
including paclitaxel, in amounts of 500 mg/l media [94]. 
The biosynthesis (Fig. 6) of paclitaxel has been studied intensively, and 
some of the enzymes involved in the pathway, like TXS (21) [95], taxadiene 5-
hydroxylase (22), cytochrome P450 reductase (23), taxane 2-O-benzoyltransferase 
(TBT) (24) [96], 10-deacetylbaccatin III-10-O-acetyltransferase (DBAT) (25) [97] 
and baccatin III-3-amino-3-phenylpropanoyltransferase (BAPT) (26) [98], have 
been elucidated. Other enzymes (taxadien-5-ol-O-acetyl transferase, taxoid 10-
hydroxylase, taxoid 2-hydroxylase, taxoid 9-hydroxylase, taxane 13-hydroxylase, 
taxoid 7-hydroxylase, and 3-N-debenzoyl-2-deoxytaxol N-benzyoyltransferase) 
have been identified and/or characterized but their order of action in the pathway 
has not been elucidated, yet [99]. More enzymes, including taxoid 1-hydroxylase, 
taxoid 9-keto-oxidase, -phenylalanoyl-CoA ligase, taxoid 2-hydroxylase, and those 
involved with oxetane ring formation, still need to be identified. 
A functional expression of the TXS was achieved in A. thaliana seedlings and 
leaves [47]. In the transgenic plant leaves, expressing the gene for TXS under an 
inducible promoter, the production of TXD reached 600 ng/gram of dry weight. 
These experiments prove that significant increases in the production of TXD can be 
accomplished by selecting temporal and spatial coordinates of TXS expression, 
establishing a platform technology for future metabolic engineering of taxanes in 
crop plants. The identification of alternative enzymes from other organisms can 
represent an additional advantage in the production of paclitaxel precursors. When 
Pacific yew extracts were treated with three enzymes originating from Nocardioides 
albus, Nocardioides luteus and Moraxella spp., a C-13 taxolase, a C-10 deacetylase, 
and a xylosidase respectively, the mix of taxanes was converted primarily to 10-
deacetylbaccatin III, and the amount of this precursor was increased by 4 to 24 times 
[100]. 
 
























Figure 6. Paclitaxel biosynthetic pathway. 21. TXS; 22. taxadiene 5-hydroxylase; 23. 
Cytochrome P450 reductase; 24. TBT; 25. DBAT; 26. BAPT. 
 
The first expression of the partial paclitaxel pathway up to TXD was 
conducted by Huang and colleagues who realized that the limiting activity of the 
cytochrome P450 in E. coli was a major drawback [92]. In 2006 the first 8 known 
genes from paclitaxel pathway (GGPPS included) were expressed in S. cerevisiae. 
The production of the early precursor of paclitaxel, baccatin III, reached 0.7 mg/l up 
to 1 mg/l of medium. The downstream products could not be measured, indicating 
that the bottleneck was encountered at the 5-hydroxylase level [101]. The 
production of TXD was further increased to 8.7 mg/L in S. cerevisiae by introducing 









The most recent experiments study E. coli via a multivariate-modular 
approach to metabolic-pathway engineering. The pathway for the production of TXD 
was divided into an upstream native and a downstream heterologous pathway. The 
promoters driving the genes expression and the replicating origins of the plasmids 
were fine-tuned to produce the maximum amount of TXD while minimalizing the 
negative feedback by the metabolite indole. The final strain could produce 
approximately one gram of TXD per liter of culture in a fed-batch bioreactor. When 
the strain was further transformed with a chimeric construct consisting of a 
truncated taxadiene 5-hydroxylase and a Taxus cytochrome P450 reductase, the 
bacteria produced taxadiene-5-ol up to 60 mg/L. The lower taxadiene-5-ol 
concentration compared to taxadiene is partially explained by the concurrent 
production of the hydroxylation byproduct 5(12)-oxa-3(11)-cyclotaxane [43]. 
Although, six more hydroxylation steps are required to obtain baccatin III, some of 
which are still unknown, this study confirms that the potential of the MEP pathway 
in E. coli can be unlocked and exploited for the marketing of microbially derived 
terpenoids both for pharmaceutical and energy purposes. 
Carotenoids are a class of tetraterpenoid pigments that are often associated 
with flowers and fruits and are known to act as potent antioxidants [102]. All 
chlorophyll-containing photosynthetic organisms produce carotenoids, as do red 
yeasts and microalgae. These compounds are used in industry as coloring agents for 
agriculture, food and cosmetics, as precursors of vitamin A in humans [103] and 
animals [104], and as feed supplements for poultry and fish [105]. Carotenoids are 
also applied in prevention of macular degeneration [106, 107] and are suggested to be 
useful as anticancer agents [108]. Within the plant, carotenoids are synthesized 
inside the plastids. Some examples of carotenoid compounds are -carotene, lutein, 
lycopene, -carotene, -cryptoxanthin and astaxanthin [109]. 
Astaxanthin (3,3’-dihydroxy-,-carotene-4,4’-dione) is an oxygenated 
carotenoid which has valuable industrial applications. It is commonly used as a food 
additive in aquaculture to obtain the desired degree of pigmentation of flesh from 
salmon and trout allowing successful marketing. The European Commission 
considers astaxanthin as a food dye and the US Food and Drug Administration 
approved it as food for animals in 2009. Furthermore, several studies on medical 
properties of astaxanthin reported anti-inflammatory, antineoplastic, antibacterial, 
photoprotective, neuroprotective and immunomodulatory effects. Currently, the 






organisms with the highest identified production of astaxanthin are the alga H. 
pluvialis and the yeast X. dendrorhous. While the astaxanthin produced in the 
esterified form by the microalga has a high stability, the carotenoid coming from the 
yeast has a better bioavailability for trout and salmon since is mainly composed of the 
free, non-esterified stereoisomer. In spite of the availability of astaxanthin in living 
organisms, 97% of the market is covered by the chemically synthesized compound. 
The chemical synthesis of astaxanthin is the cheapest process to obtain the 
carotenoid. It has been calculated that, in order to industrially compete with the 
synthetic approach, an organism would have to produce a minimum of four 
milligrams of astaxanthin per gram of cell dry weight and should be suitable for 
growth in industrial scale bioreactors [110]. The possible reduction of generated 
waste during production of the carotenoid and the possibility to increase the market 
price, by “naturally” isolating the carotenoid from microorganisms, has propelled the 
research around native and heterologous astaxanthin producers.  
Microalgae are among the most common producers of astaxanthin, and H. 
pluvialis is the dominant species for the production of this carotenoid giving yields 
ranging between 1.5% and 3% of dry weight [37]. Recently, a protocol was developed 
to genetically transform H. pluvialis and improve the astaxanthin synthesis capacity 
[111].  
The Adonis species are among the few plants to produce astaxanthin and the 
breeding of Adonis palaestina increased the carotenoid content from 7.9 to 17.9 
mg/g of dried petals [112]. Furthermore, Tobacco, Tagetes, carrots and potatoes are a 
small selection of hosts that were genetically modified to obtain astaxanthin [35, 113-
115]. 
Among yeasts, X. dendrorhous, grown in different media and under diverse 
conditions, has been the subject of several studies on the production and isolation of 
astaxanthin. The biosynthetic pathway for astaxanthin has been elucidated in this 
yeast (Fig 7). The first committed step fuses three molecules of IPP to one molecule 
of DMAPP giving GGPP (16) and is catalyzed by CrtE, a GGPP synthase. Both IPP 
and DMAPP used in this step are produced via the MEV pathway; in the second step 
two GGPP molecules are combined by the phytoene synthase CrtYB (27). Phytoene 
subsequently undergoes a desaturation step by the phytoene desaturase CrtI (28) to 
obtain lycopene. The gene crtYB also codes for a lycopene synthase which can 
catalyze the ring closure at either or both ends of the lycopene molecule. When just a 









same desaturase CrtI, is transformed into torulene and eventually into 3-hydroxy-
3’,4’-didehydro-,--caroten-4-one (HDCO). -carotene is made when both ends of 
the lycopene are closed to give a 6 membered ring. The order of the subsequent 
reactions is unknown, but it has been suggested to involve a series of hydroxylations 
and ketolyzations most likely catalyzed by CrtS, also known as astaxanthin 
synthetase, and CrtR, a cytochrome P450 reductase [116]. 
The production of astaxanthin in the wild type strain of X. dendrorhous 
ranges between 200 and 400 μg per gram of yeast dry weight, which is not enough to 
be commercially competitive with the chemically synthesized compound. Further 
chemical or physical mutagenesis led to isolation of mutants with a higher 
astaxanthin concentration, reaching a maximum concentration of one milligram of 
compound per gram of dry yeast weight [36, 117].  
Since the biosynthetic pathway for astaxanthin is known and a 
transformation protocol for X. dendrorhous has been established, genetic 
engineering has played a major role in the enhancement of production of the 
tetraterpene [118]. X. dendrorhous is the organism studied in this thesis and a more 



















Figure 7. Astaxanthin biosynthetic pathway in X. dendrorhous. 27. CrtYB; 28. CrtI. 






Selecting microorganisms to engineer the terpenoid pathways: X. 
dendrorhous as a potential platform organism 
Commonly, the hosts E. coli and S. cerevisiae are favored in metabolic 
engineering, but other hosts can be used as well. Both laboratory domestic organisms 
have been studied extensively over decades, and it is advantageous that elucidation of 
their genome, transcriptome and metabolome is nearly complete; however, in silico 
models will yet need to be provided [119]. In theory, the possibility exists to adapt 
every host for the production of natural compounds, but, as various organisms 
exhibit different genetic backgrounds, they also react differently to genetic 
manipulations and the introduced recombinant genes.  
Although nearly all organisms are able to produce terpenoid structures [11, 
120], their production strategy and structural diversity varies dramatically between 
species. Synthetic biology currently provides the tools to explore the rich variety of 
enzymes by which nature is capable of creating multiple structures. These tools can 
be used by metabolic engineers: by selecting the right host for recombinant 
expression, it is possible to increase production levels by minimal adaption of the 
genetic system. The prerequisite for metabolic engineering of a plant or 
microorganism is a profound understanding of the isoprenoid biosynthesis at a 
molecular level for the production of the different classes of terpenoids. Although, the 
primary MVA and MEP pathways leading to the biosynthesis of GPP, FPP, and GGPP 
are well characterized, the knowledge about related secondary natural product 
biosynthesis is still insufficient. Artemisinin is an excellent example of a compound 
for which early biosynthetic steps have been elucidated, but enzymes involved in the 
late-stage transformation to construct the trioxan ring skeleton remain yet unknown. 
When selecting a host other than E. coli or S. cerevisiae, it is wise to choose 
microorganisms with a natural high precursor flux. For instance, the yeast X. 
dendrorhous is industrially known for carotenoid accumulation [121-123]. Since this 
yeast is specialized to produce long-chain terpenoids, it is easier to use this ability for 
the production of terpenoid structures.  
In 1972, X. dendrorhous, also known as Phaffia rhodozyma, was isolated in 
Japan and Alaska from birch trees by Herman J. Phaff for the first time. Ten strains 
were isolated from the trees and all of them produced red pigments, reproduced by 









species of a novel genus that was given the name of its discoverer, Phaffia. X. 
dendrorhous is defined as the sexual form of P. rhodozyma and has been 
taxonomically categorized as a basydiomycota based on the cell wall structure, the 
budding process, the pigments, the urease activity and the Q-10 ubiquinone system 
[124]. It is considered to be a psychrophilic yeast with a growth temperature ranging 
between 0°C and 27°C, with an optimum, depending on the strain, between 18°C and 
22°. The cell wall polysaccharides include mainly -(1,3) and -(1,6) glucan and -
(1,3) glucan but little or no chitin is present. The cells are additionally surrounded by 
an acidic polysaccharides-based capsule. The sexual activity includes both 
sporulation and mating between two cells under starvation conditions and individual 
spores from genetically marked strains revealed evidence of karyogamy, meiosis and 
recombination. 
The genome of X. dendrorhous has not been sequenced and very little is 
known about its structural and functional organization; the ploidity level is also still 
uncertain since some strains seem to be diploid and others aneuploid. The number of 
chromosomes found in the nucleus varies from 9 to 17; furthermore, several linear 
plasmids and cytoplasmic dsRNA viruses have been found in mitochondria and in the 
cytoplasm of the yeast cells, respectively [125]. 
Astaxanthin production is the main driving force for the research on X. 
dendrorhous. Not surprisingly, most of the genes isolated and sequenced from the 
yeast genome are involved in either the MEV or the carotenoid pathway. Table 1 
provides a list of all the known genes from X. dendrorhous published in literature 
and in patents.  
The presence of introns characterizes all the sequences isolated, including 
several rDNA ORFs (which have not been included in the list, since these lack a 
complete characterization).  
The concentration of astaxanthin in the wild type strains of the red yeast 
(between 200 and 400 μg per gram of yeast dry weight) is not sufficient for the 
industrialization of this organism. In order to find a superior astaxanthin producer, 
several groups initiated research on the mutagenesis of the wild type strains or tried 
to identify a natural high-producer [36, 117]. In 1996, the first gene (act1) was 
isolated from X. dendrorhous [126], but already in 1995 a transformation protocol 
with a plasmid used for S. cerevisiae had been established. In spite of the positive 
results, the transformation efficiency was extremely low and the plasmid was lost 
easily when the selection pressure was removed [127]. To improve the transformation 






efficiency, a complete new vector was designed to allow the integration of the new 
sequence in the genomic rDNA. The mutants screening was based on resistance 
against the antibiotic geneticin, since the used vector included a resistance cassette 
with the kanamycin resistance gene (Kmr) under regulation of the promoter of the 
act1 gene [128]. The same study described a new transformation protocol that 
increased the efficiency of the process. Although, cells containing the selection 
marker for the resistance against geneticin could be isolated, the gene expression 
driven by the promoter from the actin gene was still low. To overcome the problem of 
an insufficient gene expression, Verdoes and colleagues identified and cloned the 
native gene for the glyceraldehyde-3-phosphate dehydrogenase (gpd) [129]. The 
promoter of this gene in other organisms is considered as a very strong promoter and 
has been used in several vectors to control gene expression in S. cerevisiae and 
Pichia pastoris [130, 131].  
Table 1. Sequenced and characterized genes from X. dendrorhous 
Gene (Genbank ID) Gene full name Ref. 
act1 (X89898) Actin [126] 
idi (AB019035) IPP isomerase [132] 
gpd (Y08366) Glyceraldehyde-3-phosphate dehydrogenase [129] 
crtE  GGPP synthase [133] 
eph1 (AF166258) Epoxide hydrolase [134] 
crtYB (AJ133646) Phytoene synthase/lycopene cyclase [135] 
crtI (Y150071) Phytoene desaturase [136] 
Sqs Squalene synthase [137] 
Hmc HMG-CoA synthase [138] 
Hmg HMG-CoA reductase [138] 
Mvk Mevalonate kinase [138] 
Mpd Mevalonate diphosphate decarboxylase [138] 
Fps FPP synthase [138] 
crtS (ABA43719) -carotene oxygenase (Astaxanthin synth., Cy P450) [116] 
crtR (ACI43098) Cytochrome P450 reductase [139] 
gdhA (EU7914561) Glutamate dehydrogenase [140] 
Xd-INV (ACL79833) -fructofuranosidase [141] 
TEF-1 Translation elongation factor 1- [142] 










With the identification of a strong promoter and the optimization of the 
transformation protocol, the identification, isolation and overexpression of the genes 
involved in the astaxanthin pathway became easier and faster. Sequences were 
obtained and overexpressed in other organisms, like S. cerevisiae [144, 145] or used 
in knock-out experiments to identify the different phenotypes caused by the absence 
of particular genes [121]. Some of these studies highlighted the possibility of 
alternative splicing of some genes, producing different proteins with different 
functions. A good example is given by the crtYB gene coding for two proteins 
involved in the astaxanthin pathway, a phytoene synthase (CrtY) and a -carotene 
oxygenase (CrtB) [146]. 
In addition to isolation of natural or induced high astaxanthin producers and 
the genetic engineering of the wild type strains of X. dendrorhous, several studies 
have focused on growth conditions and media that would increase the carotenoids 
production in the red yeast. For example, Marcoleta and colleagues indicated ethanol 
as a strong inducer and glucose as a repressor of astaxanthin production [143]. 
Citrate and glutamate, precursors of the carotenogenesis, were also found to increase 
astaxanthin content when added to the cultures [147, 148]. Rodríguez-Sáiz and 
colleagues, together with the review published by Schmidt and colleagues, have 
summarized the major accomplishments in the industrial production of astaxanthin 
and provided an extensive overview of the studies performed on X. dendrorhous 
[149, 150].  
In addition to the research on astaxanthin production in X. dendrorhous, a 
few studies have focused on proteins outside of the carotenoid pathway, like the 
extracellular -fructofuranosidase, involved in the hydrolyzation of sucrose-like 
sugars, or the pyruvate decarboxylase induced by glucose feeding [141]. 
One aspect that has not been investigated is exploitation of the terpene 
precursors pool present in X. dendrorhous. As seen in the literature, Phaffia’s 
potential to produce terpenoid structures is still far from being fully exploited. The 
presence of the MEV pathway, the knowledge about the carotenogenesis and the 
availability of transformation vectors and protocols provide us with the necessary 
techniques to investigate X. dendrorhous as a platform organism for the production 
of terpenes. By expressing different terpene synthases in the red yeast, knocking out 
the carotenoid pathway at different stages, comparing the production of the same 
compound in different microorganisms and examining the possibility of producing a 






complete terpene-based drug we show that Phaffia is indeed a suitable host for the 















HETEROLOGOUS EXPRESSION OF PENTALENENE 
SYNTHASE (PSS) FROM STREPTOMYCES UC5319 IN 
XANTHOPHYLLOMYCES DENDRORHOUS 
 
















For the first time, the pentalenene synthase (PSS) gene from Streptomyces 
UC5319 was expressed in Xanthophyllomyces dendrorhous, a native producer of 
astaxanthin. For the expression of the gene and the concurrent knock out of the 
native crtE or crtYB genes, two new vectors were engineered and used for the 
transformation of the wild-type strain of X. dendrorhous. The transformations 
resulted in white colonies, showing a complete shutdown of the carotenoid 
production. Furthermore, an additional vector was constructed for the insertion of 
the PSS gene in the rDNA of the yeast. All the mutant strains produce the 
sesquiterpene pentalenene and show no difference in growth when compared to the 
wild-type strain. In this report, we demonstrate that X. dendrorhous is a suitable 
host for the expression of heterologous terpene cyclases and for the production of 
foreign terpene compounds. 
 
 







Xanthophyllomyces dendrorhous belongs to the phylum of the 
basidiomycota and shows a characteristic red pigmentation [125] given by the 
carotenoid astaxanthin, produced by the yeast in response to oxidative stress [4]. 
Since the market size of astaxanthin in 2007 reached nearly 220 million US dollars 
[150], the improvement of the production of the tetraterpene in X. dendrorhous has 
been the main aim of the research performed on this yeast. Screening of mutants 
[151], genetic engineering [121] and optimization of medium and growth conditions 
[110, 152] represented the most common approaches chosen to increase the yield of 
astaxanthin from X. dendrorhous. Integrative plasmids and a transformation 
protocol have been developed for the study of the carotenoid pathway. The 
biosynthetic pathway for the production of carotenoids in X. dendrorhous has been 
elucidated [118] and some of the genes have been transferred to Saccharomyces 
cerevisiae [144]. The genes crtE, crtI, crtYB, crtR and crtS were identified, 
overexpressed and/or deleted in X. dendrorhous, yielding different phenotypes 
caused by the modified concentrations and ratios of the carotenoids in the yeast [121, 
139, 153, 154]. 
The production of carotenoids by X. dendrorhous implies the presence of an 
upstream mevalonate (MEV) pathway that can provide the precursors, isopentenyl 
diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), for the formation of 
terpenes [155]. IPP and DMAPP constitute the building blocks for several different 
compounds, like volatile scented monoterpenes [156] sesquiterpenes with 
antimalarial or antibacterial properties [87, 157], sterols for membrane fluidity [2] 
and diterpenes with antineoplastic characteristics [43] While some of the terpenes 
are widely available in nature, e.g. limonene and menthol, some others are produced 
by the native host in low amounts or the extraction from the natural source is too 
inefficient. Thus, the need arises for alternative methods of production for such 
precious terpenoid drugs.  
One of the potential strategies is genetic engineering of heterologous hosts 
for the production of molecules of interest or precursors that can be then easily 
chemically modified [158-160]. The metabolic engineering approach has been 
extensively applied, mostly to Escherichia coli and S. cerevisiae. While both models 









advanced genetic engineering tools, they may show a low natural terpene flux [155]. 
A faster and less invasive solution might come from genetically engineering 
organisms that already have a higher level of terpene precursors, for example, X. 
dendrorhous.  
We decided to use the pentalenene synthase (PSS) gene in our new 
expression vector as a proof that X. dendrorhous can functionally express a 
heterologous terpene cyclase. PSS is a prokaryotic sesquiterpene cyclase that 
catalyzes the formation of pentalenene using farnesyl diphosphate (FPP) as substrate 
[161] (Fig. 1). The gene is relatively short (~1 kb) and it was isolated from 
Streptomyces UC5319.  
For the expression of the cyclase, two different approaches were chosen. In 
the first strategy, the gene was inserted in one of the two new vectors engineered 
using pPR2TN as a template [135] allowing the insertion of the expression cassette 
into the genes crtE or crtYB. As second approach, a modified pPRcDNA1crtE vector 






Figure 1. Conversion of FPP towards pentalenene catalyzed by pentalenene synthase, PSS.  
 
Materials and methods 
Strains and culture conditions 
E. coli DH5 strain was used for the cloning steps; bacteria were grown in LB 
(1% Trypton, 0.5% Yeast Extract, 1% NaCl) with 100 mg/ml ampicillin in a shaking 
incubator at 37°C, 250 rpm. 
The wild type strain X. dendrorhous CBS 6938 (ATCC 96594) was used as 
control and for all transformation procedures. YPD (1% Yeast Extract, 2% Peptone 
and 2% Glucose) medium with and without 40 μg/ml geneticin (G-418 Sulfate, 






Gibco) was used for the yeast growth in a shaking incubator at 21°C, 180 rpm. The 
ratio between medium and air space in the flasks was always kept at 1:10. 
 
Engineering of recombination vectors and transformation of X. 
dendrorhous 
pGEMT vector was used as a backbone for the engineering of all the vectors 
in this study. The cassette for the resistance against geneticin was amplified from the 
plasmid pPR2TN [135]. 
The expression cassette was created by fusing the GPD promoter to the GPD 
terminator sequence from pPR2TN. The product presented a small multiple cloning 
site between the promoter and the terminator sequences with the unique restriction 
sites for NheI, HpaI, AvaI and XhoI, and was flanked by restriction sites for SpeI and 
BamHI. The complete cassette was ligated into pGEMT; the construct was then 
digested with NdeI and SpeI and ligated to the resistance cassette that had been cut 
with the same restriction enzymes, resulting in one complete vector, pMCS. 
The genes used as recombination sequences for the vectors were amplified 
from genomic DNA extracted from X. dendrorhous. The crtE gene, flanked by the 
sequence recognized by EcoRI, was amplified and ligated into pGEMT (pCrtE). Part 
of the crtYB gene was amplified and a BamHI site was inserted in the middle of the 
fragment by overlapping PCR; the gene was, then ligated into pGEMT (pCrtYB). 
The PSS gene (GenBank ID: U05213.1) was a kind gift of Prof. Claudia 
Schmidt-Dannert from University of Minnesota. After amplification and ligation in 
pGEMT, the gene was excised with NheI and XhoI and ligated into the multiple 
cloning site of the pMCS, which had been previously digested with the same enzymes, 
resulting in the new construct pPSS. The plasmid was digested with BamHI and 
ligated in pCrtE and pCrtYB, yielding the two final constructs pCrtE-PSS and 
pCrtYB-PSS, respectively (Fig. 2 A, B). 
The pPRcDNA1crtE plasmid [153] was a kind gift of Prof. Sandmann, Goethe 
Universität, Frankfurt. The crtE gene was excised from the plasmid using EcoRI and 
SacI and replaced with the restriction sites for NheI and XhoI that were then used to 
clone the PSS gene giving the new vector pPR-PSS. pPR-PSS was linearized with 









Transformation of X. dendrorhous was performed according to the protocol 
of Wery and colleagues [128]. After the transformations with pCrtE-PSS and pCrtYB-












Figure 2. Scheme of the EcoRI fragment of pCrtE-PSS (A) and pCrtYB-PSS (B) vectors and of 
the linearized pPR-PSS vector (C) used for the transformation of X. dendrorhous. The crosses 
indicate the double crossing over events with the genomic DNA that will have to occur in order 
to obtain the stable mutants.  
 
GC-MS analysis of organic layer  
Dodecane was added to 10 ml of cultures in the concentration of 5% and 
hexadecane had a final concentration of 37.7 μg/ml of medium. Cultures taken at 
different time points were pelleted for 10 minutes at 3000 xg; the upper dodecane 
layer was isolated and diluted 1:10 in ethyl acetate. The diluted dodecane extract was 
analyzed in total ion scan using a ZB-1ms dimethylpolysiloxane column 
(Phenomenex 0.25 mm inner diameter, 0.25 μm thickness, 15 m length) on a 
Shimadzu GCMS-QP5000. Two microliters of solution were injected splitless in the 
GC using helium as carrier gas. The injector temperature was 250°C; the oven initial 
temperature was 50°C with an increment of 5°C/min up to 105°C and then up to 
200°C with an increase of 30°C/ min. The solvent cut-off was of 10 minutes and 30 
seconds due to high dodecane content. 
A B
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Mutants in the carotenoid pathway 
The transformations of Xanthophyllomyces dendrorhous resulted in two 
different mutants in the terpenoid pathway. The geranyl-geranyl diphosphate 
synthase (GGPPS) gene crtE was the target for the creation of the first mutant, crtE, 
while the second mutated strain (crtYB) was characterized by the insertion of the 
resistance cassette in the gene crtYB, coding for the protein acting both as phytoene 
synthase and as lycopene cyclase. Both crtE and crtYB showed a white colony 
phenotype in contrast to the pink color of the wild type, as can be seen in Figure 3. 
This clear lack of carotenoids, in addition to the ability to grow on selective medium, 
was a strong proof that the integration of foreign DNA had occurred. The presence of 
the resistance cassette in the genomic DNA was confirmed by PCR (data not shown). 
In order to establish whether the lack of carotenoids in the mutants was 
affecting the growth of the yeast, a time course experiment was performed (Fig. 4). 














Figure 3. Phenotype of wild type and mutant colonies. Strains: 1, WT; 2, crtYB; 3, crtE; 4, 
crtYB-PSS; 5, crtE-PSS; 6, pPR-PSS. YPD medium was used to resuspend colonies grown 
on plates; approximately 10 μl of the solutions were spotted on a new YPD plate and let grow at 


















Figure 4. Growth curves of wild type (closed circles), crtYB (open circles), crtE (closed 
triangles) crtYB-PSS (open triangles), crtE-PSS (closed squares) and pPR-PSS (open 
squares) strains grown in YPD medium, with geneticin where necessary. Overnight cultures 
were diluted in 10ml of medium to an OD of 0.05 for each culture and each time point. 
Experiments were performed in duplo. 
 
X. dendrorhous strains transformed with PSS gene  
The vectors for the expression of the pentalenene synthase (PSS) gene in X. 
dendrorhous were engineered starting from the constructs used to create the 
mutants crtE and crtYB. The new expression cassette was introduced in the 
vector, flanking the antibiotic resistance region (Fig. 2 A, B). To be able to transform 
X. dendrorhous, both pCrtE-PSS and pCrtYB-PSS were digested with EcoRI and the 
fragment was purified and concentrated. Two mutants lacking carotenoids (white) 
but containing the PSS gene were isolated after transformation of the wild-type strain 
and were named crtE-PSS and crtYB-PSS. The new strains showed the same color 
phenotype (Fig. 3) and the same growth curves (Fig. 4) as the respective mutants 
without the PSS gene. 
In order to evaluate the effect of the production of carotenoids on the 
pentalenene concentration, we constructed the vector pPR-PSS (Fig. 2 C) and used it 
for the transformation of the wild type X. dendrorhous resulting in PSS expression 
without interference with the carotenoid pathway. As shown in Figure 3, this 
mutant (pPR-PSS) exhibits similar pigmentation as the wild type strain, and the 
growth curve is comparable to the one obtained with the non-transformed yeast (Fig. 
4). 






Production of pentalenene in crtE-PSS, crtYB-PSS and pPR-
PSS 
The dodecane layer, expected to harbor the pentalenene, was isolated from 
the cultures after 24, 48, 72 and 96 hours cultivation. The chromatograms of the 
diluted dodecane from crtE-PSS, crtYB-PSS and pPR-PSS showed a peak at about 
11.5 minutes that was absent in the wild type strain, crtE and crtYB (Fig. 5). The 
fragmentation pattern of the peak (Fig. 6) matched the pentalenene pattern as 
reported in the literature (Fig. 7, adapted from [162]) and presented two 
characteristic peaks for sesquiterpenes (m/z 204 and m/z 189) in the percentage of 
68% and 47.6%, respectively, when considering the base peak (m/z 105.1) as 100%. 
Other major peaks could be found at m/z 175.1 (13.1%), 161.2 (41.1%), 147.2 (73.7%), 
119.2 (57.2%) and 91.1 (91.3%). In order to be able to compare the production among 
the different strains, hexadecane was added at known concentration to the cultures 
as internal standard together with the dodecane. The concentration of pentalenene in 
the cultures was increasing with the optical density of the cultures as shown in 
Figure 8, which is in concert with the constitutive regulation reported for the GPD 










by the arrow) is 
found at 11.5 
minutes from 
injection time. 
The peak at 
about 13.5 
















































Figure 8. Pentalenene 
production by pPR-PSS 
after 24, 48, 72 and 96 
hours from inoculation 
point. The retention 
time of the pentalenene 
is 11.48 minutes. 







X. dendrorhous has been the target of studies focusing on the biosynthesis 
and production optimization of the dye astaxanthin. Experiments involving genetic 
engineering of this yeast have converged towards the identification of the genes 
involved in the carotenoid pathway and the overexpression or deletion of those genes 
to analyze the differences in carotenoids production. In spite of the presence of tools 
for the transformation of the yeast, no effort has been put into expressing 
heterologous genes in X. dendrorhous, except for the sequences conferring resistance 
against geneticin and hygromycin [128, 139].  
Here we report for the first time the production of a heterologous terpene 
cyclase in X. dendrorhous. We designed and engineered two new vectors for the 
functional expression of the heterologous PSS and the concurrent knocking out of 
one of the host’s genes. The mutants obtained after selection on antibiotic showed a 
clear change in phenotype, which is due to the insertional inactivation of crtE or 
crtYB. The strains switched from the wild-type orange pigmentation to a completely 
white color, indicating a complete lack of astaxanthin and of any other coloring 
carotenoid. Carotenoids, like astaxanthin, are known to be produced by the yeast in 
response to oxygen reactive species produced under high oxygen conditions or during 
cell aging [4]; we demonstrated that the absence of carotenoids did not seem to affect 
the growth of the mutants since they followed the same growth curve and reached the 
same final OD as the wild type strain (Fig. 4).  
The production of pentalenene could easily be revealed by culturing the yeast 
in presence of dodecane, which trapped the volatile compounds produced by the 
yeast. Detection by GC-MS did not show other terpenoids as by products, therefore 
we assume that pentalenene was the only biosynthesized terpenoid produced by the 
yeast that could be captured in the dodecane layer or at least detected. 
The yield of pentalenene in the mutant strains ranged from 0.25 to 0.68 
mg/L when compared with hexadecane as internal standard. The pPR-PSS strain 
showed a higher production compared to the other two mutant strains. The reason 
for this difference in production may be the integration of multiple copies of the gene 
in the genomic rDNA sequences. To support this theory, preliminary results in our 
lab show that low production of pentalenene in integration strains is probably caused 









concentrations of geneticin only colonies with a higher copy number of the genes 
could grow, and a screening of those colonies showed that the production of the 
sesquiterpene could reach 4.8 mg/L, which corresponded to 0.37 milligrams of 
pentalenene per gram of dried yeast.  
The expression of a terpene cyclase in X. dendrorhous opens a new path 
toward the utilization of this yeast as a potential platform organism for the 
production of terpene based drugs. The possibility to knock out the carotenoid 
pathway and, thus, to channel the upstream precursors towards the production of 
new metabolites provides an additional advantage over the organisms that have been 
exploited until now for the terpene production. Breitenbach and colleagues have 
calculated that the wild type strain of X. dendrorhous grown in a poor medium can 
produce an average of 694 micrograms of total carotenoids per gram of yeast dry 
weight [153]. Furthermore, concentrations of astaxanthin of over 6.6 milligrams per 
gram of dry yeast weight could be obtained growing X. dendrorhous with different 
media, light and oxygen conditions [110].  
These results confirm that the production of foreign terpenes in X. 
dendrorhous is not limited by the concentration of precursors, but rather by the gene 
expression driven by a weak regulating sequence. With a stronger promoter and with 
a codon optimized gene, the pentalenene production could reach even higher yields.  
The maximum concentration of pentalenene we obtained in X. dendrorhous 
is still 20 times less than the maximum concentration of astaxanthin isolated from 
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PRODUCTION OF -CUPRENENE IN 
XANTHOPHYLLOMYCES DENDRORHOUS: A STEP CLOSER 
TO A POTENT TERPENE BIOFACTORY 
 
















Background: The red yeast Xanthophyllomyces dendrorhous is a natural 
producer of the carotenoid astaxanthin. Because of its high flux, the native terpene 
pathway leading to the production of the tetraterpene is of particular interest as it 
can be redirected toward the production of other terpene compounds. The genetic 
tools for the transformation of the yeast with the concurrent knock-out of genes 
involved in the astaxanthin biosynthesis are made available and here we show that 
the production of the sesquiterpene -cuprenene is possible in mutant strains of X. 
dendrorhous transformed with the Cop6 gene originating from the fungus Coprinus 
cinereus. For the evaluation of the production levels, we chose to express the same 
gene and analyze the accumulation of -cuprenene in Escherichia coli and 
Saccharomyces cerevisiae, as well. Here we propose that X. dendrorhous is a 
candidate in the search for the potential platform organism for the production of 
terpenes. 
Results: All three X. dendrorhous mutants functionally express the Cop6 
gene and accumulate -cuprenene. The production of -cuprenene in the red yeast 
reached 80 mg/L, which represents a far higher concentration compared to the levels 
obtained in the E. coli and S. cerevisiae mutants. At this expression levels the pool of 
terpene precursors has not become a limiting factor in the X. dendrorhous mutants 
since the expression of the Cop6 gene in the genomic rDNA of the yeast allows 
production of both -cuprenene and astaxanthin without affecting the growth or the 
accumulation levels of both compounds. 
Conclusions: We have shown that X. dendrorhous can produce -cuprenene, 
and the results here presented, next to the capability of accumulating at least two 
more non-native sesquiterpenes, demonstrates the high potential of this yeast to 
become an interesting terpene-based drugs producer. 
 







Since ancient times, microorganisms have been used to produce bread, wine 
and dairy products in order to improve the quality of food and its nutrients. Today, 
microbes are utilized for the manufacture of a wide variety of fine or bulk chemicals 
including antibiotics [163, 164], vitamins [165], biofuels [166, 167], biodegradable 
and biocompatible plastics from waste [168] and terpene-based drugs [43, 89]. 
Originally, the choice for a production host was dictated by the ability of the 
organism to produce the desired compounds but in most cases the concentration of 
the chemicals of interest was not sufficient to cover the market demand. 
With the development of genetic engineering, new tools became available to 
overcome these obstacles. The possibility of transferring single genes or even 
complete pathways to other microorganisms led to improved yields or easier 
bioprocessing conditions. Furthermore, metabolic engineering allowed the 
enhancement of the yields in the native hosts by finely tuning the metabolic networks 
of the cells towards the optimized production of the specific compound. More 
recently, the combination of synthetic biology and metabolic engineering has resulted 
in the creation of hosts capable of producing a non-native compound with high 
efficiency obtainable only by optimizing the native pathways of the cells [169]. 
The majority of the yeast or bacterial strains used by industry have been 
selected for the several advantages they deliver: they are easy to cultivate, they can 
grow on cheap media, they are generally regarded as safe (GRAS status) and their 
metabolic pathways are easy to modify via genetic engineering. 
Xanthophyllomyces dendrorhous, a red basidiomycetous yeast, represents one 
of the microbial strains already used in industry and shares all the aforementioned 
advantages [150]. Today, X. dendrorhous is grown at industrial scale for its native 
capability to produce the valuable carotenoid astaxanthin.  
Carotenoids, together with several other pharmaceutically important 
compounds, like artemisinin and paclitaxel, belong to the natural compounds class of 
the terpenes [155]. Several efforts have been put in the engineering of a platform 
organism for the production of industrially important terpenes [43, 89]. 
We hypothesize that, since X. dendrorhous can produce high levels of 
astaxanthin, which shares the same precursors with all other terpenes, it can also 









The red yeast was already shown to be able to functionally express the 
pentalenene synthase from a Streptomyces strain involved in the biosynthesis of the 
antibiotic pentalenolactone [170]. In order to further evaluate the potential of the red 
yeast as a platform organism for terpenes, we expressed the sesquiterpene cyclase 
Cop6 in X. dendrorhous mutant strains. The protein Cop6, originating from the 
fungus Coprinus cinereus, produces the cyclized sesquiterpene -cuprenene, which is 
the basic structure for the formation of lagopodin A, an antimicrobial sesquiterpene 
quinone [162]. We also compared the accumulation levels of -cuprenene with two of 
the most industrially utilized microbial strains, E. coli and S. cerevisiae.  
Results  
Production of cuprenene in E. coli  
Isolation of volatile terpenoids in E. coli via addition of a dodecane organic 
phase to the liquid cultures has been shown to be extremely efficient [42]. We have 
decided to adopt the same strategy to capture the -cuprenene produced by the E. 
coli strains transformed with the Cop6 gene. In order to be able to compare the levels 
of -cuprenene at the different time points and from different organisms we added 
hexadecane in known concentrations, as an internal standard, to the dodecane. 
Twenty hours after induction of the expression, cells reached the highest 
density and they started dying after 30 hours. After 48 hours the concentration of 
cuprenene, based on the internal standard, reached approximately 0.25 mg/L of 







Figure 1. Cuprenene production 
during time course with E. coli 
pHis8Cop6 






Growth curves and -cuprenene production from S. cerevisiae and X. 
dendrorhous in rich medium  
After the separate transformations of X. dendrorhous wild-type strain with the 
vectors pCrtE-Cop6, pCrtYB-Cop6 and pPR-Cop6, one colony from each 
transformation plate was chosen to be grown and analyzed. As expected, since the 
astaxanthin pathway was disrupted (Fig. 2), on the plates used to select E-Cop6 
and YB-Cop6, the mutant colonies presented a white phenotype. In contrast, 
XdCop6 colonies, transformed with pPR-Cop6, in which the carotenoid pathway was 
not modified (Fig. 2), shared an orange pigmentation with the wild type strain. 
The S. cerevisiae mutant, ScCop6, was isolated after transformation of the wild 
type strain of S. cerevisiae with the plasmid p426GPD-Cop6, which allows 
constitutive expression of the Cop6 gene.  
A time course analysis was performed on the ScCop6 and on the three X. 
dendrorhous mutant strains, XdCop6, E-Cop6 and YB-Cop6. In order to obtain a 
high biomass, all the strains were grown in the rich YPD medium. The time course 
consisted of four sampling times after the inoculation in fresh medium; we chose 
24h, 48h, 72h and 96h to be able to observe all the steps of the growth curve. Figure 






(A) In the mutant 
XdCop6, the native 
astaxanthin 
pathway has not 
been modified but 
the gene Cop6 has 
been integrated in 
the rDNA of the 
yeast allowing the 
mutant to produce 
both astaxanthin 
and -cuprenene. 
(B) In the strain 
E-Cop6 the Cop6 
gene has been 
inserted in the 
crtE gene causing 
the disruption of 
the carotenoid 









GGPP synthesis level. (C) When Cop6 is inserted in the crtYB gene, the YB-Cop6 strain is 
created. While there is still expression of the GGPPS, phytoene cannot be produced anymore, 












Figure 3. OD600 and cell dry weight of ScCop6, E-Cop6, YB-Cop6 and XdCop6 in 10 ml of 
YPD medium. 
 
The three X. dendrorhous strains exhibit similar curves with respect to the 
OD600 and to the cell dry weight. In contrast, the S. cerevisiae mutant reaches a 
higher optical density but accumulates a lower biomass compared to the three X. 
dendrorhous mutants. 
The diluted dodecane solutions from the transformed S. cerevisiae and from 
the wild type and mutant strains of X. dendrorhous were analyzed by GCMS, and a 
single peak appeared in the chromatograms from the mutants at 12.8 minutes (Fig 
4). The fragmentation pattern of the peak was compared to the pattern 
corresponding to -cuprenene produced in S. cerevisiae (Fig. 5). The mass and the 
relative ratio of the fragment peaks matched between the two patterns, allowing us to 
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Figure 4. Chromatograms of the diluted dodecane from (A) X. dendrorhous wild type strain 
and (B) E-Cop6. The peak at 13.5 minutes is the hexadecane used as internal standard. The 
-cuprenene has a retention time of approximately 12.8 minutes. 
 
The time-course production of -cuprenene in the four strains is represented 
in Figure 6. The level of the sesquiterpene in S. cerevisiae sharply increased after 24 
hours to reach a maximum of 6.6 mg/ L on the second day of culturing and then 
appeared to decrease during the following two days.  
The -cuprenene production in the three X. dendrorhous strains showed ten 
times higher levels with a major increase between 24 and 48 hours, as well. In 
contrast to S. cerevisiae, XdCop6, E-Cop6 and YB-Cop6 constantly produced -
cuprenene during the complete time course. The accumulation of the sesquiterpene 
appeared to be consistent in all the three X. dendrorhous strains and was directly 
proportional to the cell mass, in particular in the first three days after inoculation. 
The highest yield was obtained after 96 hours with the XdCop6 strain and 
corresponded to almost 80 mg/L of culturing medium. E-Cop6 could produce up to 
70 mg of -cuprenene per liter of medium and YB-Cop6 74 mg/L, both after 







Figure 5. Fragmentation 
patterns. (A) -cuprenene from 
ScCop6; (B) peak at 12.8 



















cuprenene in rich 
YPD medium 
 
Growth curves and -cuprenene production from S. cerevisiae and X. 
dendrorhous in minimal medium  
The ScCop6 mutant was selected on medium lacking uracil in order to allow 
only the colonies containing the plasmid to grow. The rich YPD medium contains all 
the necessary nucleotides, thus the selective pressure on the S. cerevisiae mutant 
strain grown in this medium was inexistent. For this reason, we decided to grow all 
the strains in a minimal medium lacking uracil which would allow a more accurate 
comparison between the ScCop6 and the three X. dendrorhous mutants. The same 
settings chosen for the time course in rich medium were applied for the growth and 
-cuprenene production analysis in minimal medium. 
An overall lower cell mass and OD600 compared to rich medium was observed 
for all the strains. S. cerevisiae started growing already after 24 hours while XdCop6, 
E-Cop6 and YB-Cop6 showed a lag phase between 0 and 24 hours and a log 
growth between 24 and 48 hours (Fig. 7). In minimal medium E-Cop6 exhibited a 
slightly reduced cell growth compared to XdCop6 and YB-Cop6  
The accumulation of -cuprenene in the three X. dendrorhous strains was 
significantly lower than the concentration obtained in YPD reaching a maximum of 
20 mg/l (Fig. 8) for YB-Cop6. When ScCop6 was grown in minimal selective 
medium, the sesquiterpene production increased nearly to 12 mg of -cuprenene per 
liter of medium.  











































Microscopy analysis of ScCop6 and XdCop6 
Figures 3 and 7 indicate that S. cerevisiae and X. dendrorhous are 
characterized by a different growth rate and optical density. For a better 
understanding of the differences between the two yeasts, we performed a microscopy 
analysis on the strains ScCop6 and XdCop6. 
A Burke chamber was used to count the yeast cells. In spite of the macroscopic 
red pigmentation of XdCop6, the cells appeared white under the microscope white 
light. After counting samples in duplo from ScCop6 and XdCop6 and calculating the 
cell numbers, we observed that one OD600 unit in S. cerevisiae corresponded to 3 x 
107 cells per milliliter, consistent with the data available in literature [171]. In 
contrast, the number of X. dendrorhous cells counted in one milliliter of culture with 
the same optical density was 4.8 x 106.  
To further ascertain the morphological differences between ScCop6 and 
XdCop6, we compared the average cells sizes. Figure 9 compares the pictures of the 
two strains after four days of growth; the same magnification was used to visualize 
the cells. Cells from XdCop6 are round shaped and have a granular appearance, while 
ScCop6 cells, although showing a similar round morphology, show a more 
homogeneous cytosol. On average, the size of X. dendrorhous cells was 10 μm in 
diameter; S. cerevisiae cells were smaller with a size ranging between 7 and 8 μm. 
Not only ScCop6 cells were on average smaller than X. dendrorhous, but they also 








Figure 9. Microscopy photographs. (A) ScCop6 and (B) XdCop6. 
 







E. coli and S. cerevisiae are two model organisms that also serve as industrial 
cell factories for the production of a wide variety of compounds ranging from 
pharmaceutically active substances to food ingredients and biofuels.  
In spite of the fact that X. dendrorhous has not been studied as extensively as 
E. coli or S. cerevisiae, it shows great potential to become a platform organism for 
terpene production [170]. In order to assess the value of the red yeast as a cell 
factory, we expressed the Cop6 gene in the three X. dendrorhous mutants and 
compared the production of -cuprenene with E. coli and S. cerevisiae strains 
expressing the same gene. 
The cDNA from the Cop6 gene was expressed by all X. dendrorhous mutants, 
whereas the genomic version of the gene, when transferred to the red yeast, did not 
result in -cuprenene accumulation (data not shown) indicating that X. dendrorhous 
cannot correctly splice the gene from C. cinereus. 
When grown in rich medium, the X. dendrorhous mutant strains showed very 
similar growth rates: they reached OD600 values of 20 and produced a maximum of 12 
grams of cell dry weight per liter of culture. Similarly, when looking at the -
cuprenene production, the three strains XdCop6, E-Cop6 and YB-Cop6 did not 
show big differences among each other, with levels of the sesquiterpene ranging from 
70 to 80 mg of compound per liter of medium.  
Comparing figures 3 and 7, it is clear that, differently from the experiments in 
the rich medium, the three X. dendrorhous strains shared an altered growth behavior 
in the minimal medium. While XdCop6 and YB-Cop6 reached a maximum cell dry 
mass of nearly 5 g/L, E-Cop6 could not produce more than 3.5 g of dry cells per liter 
of medium. Concomitantly, the concentration of -cuprenene in the dodecane was 
reduced to values ranging from 15 to 21 mg/L of culture. The decrease in 
sesquiterpene accumulation can partly be explained by the reduced cell mass and 
partly by the lower concentration of nutrients in the minimal medium which would 
induce the cells to minimize the energy consumption by shutting down unnecessary 
pathways.  
When comparing cell mass accumulation and -cuprenene production in all X. 
dendrorhous, E. coli and S. cerevisiae strains, the prokaryote showed the lowest 









glucose in its growth medium, while the limited sesquiterpene production is due to 
the lower terpene flux in E. coli compared to the two eukaryotes. 
The differences in growth curves and dry weight between the X. dendrorhous 
and the S. cerevisiae strains seem to have morphological reasons. X. dendrorhous 
cells are on average bigger than S. cerevisiae ones [172] and at the same optical 
density S. cerevisiae cell counts are almost 10 times higher than in X. dendrorhous 
cultures, meaning that the same OD600 value corresponds to more S. cerevisiae cells 
than it does for X. dendrorhous. Since, at the beginning of the time course 
experiments, the initial OD600 for all the strains was set at 0.05, the number of cells 
initially transferred to the fresh medium was higher in ScCop6 than in all the X. 
dendrorhous mutants. This would explain the delay in growth we observed for 
XdCop6, E-Cop6 and YB-Cop6 compared to ScCop6. Additionally, the higher cell 
mass accumulation observed in the X. dendrorhous strains compared to S. cerevisiae 
may be due to the red yeast’s bigger sized cells rather than to a higher number of 
cells.  
The highest -cuprenene production levels were obtained with the X. 
dendrorhous strains both in the rich and in the minimal medium experiments. 
Remarkably, in the YPD medium the gap in sesquiterpene accumulation between the 
red yeast and the S. cerevisiae strain was far more pronounced. We assume that, 
since the complete medium does not allow selective pressure on ScCop6, which was 
isolated by its ability to grow on minimal medium lacking uracil, the strain might 
have undergone a reduction in plasmid copy number. 
While ScCop6 mutants contain an average of 20 copies of Cop6, the X. 
dendrorhous white mutants possess just one copy of the gene since the 
recombination of the constructs can occur only once in the single crtE or crtYB 
genes. In order to obtain a mutant with a higher number of integrations of the gene 
in the genomic rDNA, we transformed the X. dendrorhous wild type strain with a 
higher concentration of the DNA fragment from the pPR-Cop6 vector and selected 
the transformants on YPD medium containing a concentration of geneticin 5 times 
higher than normal, hoping for gene amplification. Unfortunately, no colony grew 
after this transformation and we could not evaluate the effect of more gene copies on 
the -cuprenene accumulation.  
Nevertheless, we can safely assume that the concentration of the precursors is 
not a limiting factor in the sesquiterpene production in X. dendrorhous, since the 






strain XdCop6 can easily sustain the production of both -cuprenene and 
astaxanthin, especially when grown in the YPD rich medium. The production of both 
terpene compounds in XdCop6 confirms the hypothesis that a higher gene copy 
number would positively influence the -cuprenene production in X. dendrorhous. 
In conclusion, X. dendrorhous shows great promise since it has the GRAS 
status, it grows at room temperature in minimal media, and it has already been used 
by industry for the production of astaxanthin. We discovered that it can produce at 
least three non-native sesquiterpenes, pentalenene [170], -cuprenene and cubebol 
(S1-7). Furthermore, X. dendrorhous is the best microorganism, among the ones we 
have analyzed, to be used for the production of -cuprenene. A better understanding 
of the molecular biology of this yeast will prove useful for the identification of 
stronger promoters for a higher gene expression.  
In light of the aforementioned advantages and of the provided results, X. 
dendrorhous is an interesting candidate for being used as a cell factory for the 
production of terpenes. 
 
Methods 
Strains and culture conditions 
The E. coli strain DH5 was used for the cloning processes, while the strain 
BL21 (DE3) was transformed and cultured for the time course experiments. S. 
cerevisiae MRG 5 #502 (MATa, ura3-52, leu2-1, trp1-36, his3-200, Dade2) was 
used for the transformation and time course analysis. X. dendrorhous wild type 
strain (CBS 6938) was used for the transformations and as negative control for all 
experiments. Both E. coli strains were grown in LB (10 g/L Trypton, 5 g/L Yeast 
Extract, 10 g/L NaCl) with 30 mg/ml kanamycin. The rich medium for S. cerevisiae 
and X. dendrorhous was YPD (10 g/L Yeast Extract, 20 g/L Peptone and 20 g/L 
Dextrose) with additional 40 mg/ml geneticin (G-418 Sulfate, Gibco) only for the 
selection and growth of the X. dendrorhous mutants. The minimal medium for S. 
cerevisiae consisted of 13.4 g/l Yeast Nitrogen Base without amino acids, 20 g/L 
Dextrose, 100 mg/L leucine, 40 mg/L histidine, 40 mg/L tryptophan and 40 mg/L of 









the minimal medium for X. dendrorhous and geneticin was added to the medium for 
the culturing of the mutants. 
Construction of the E. coli strain EcCop6 and time course analysis 
The plasmid pHis8Cop6 was a kind gift of Prof. Claudia Schmidt-Dannert from 
University of Minnesota and it contains the cDNA sequence of the Cop6 gene from 
Coprinus cinereus under the control of the T7 promoter. E. coli BL21 (DE3) colonies 
containing pHis8Cop6 were selected on LB plates with kanamycin. 
One transformed colony, EcCop6, was chosen for the time course analysis and 
a seed culture was started over night in LB plus kanamycin. The fresh cultures were 
inoculated and grown to OD600 0.5 and then 1 mM isopropyl -D-1-
thiogalactopyranoside (IPTG) was added for the induction of expression of the Cop6 
gene. The time course was performed in duplo and consisted of six 100-ml flasks with 
10 ml of LB medium plus kanamycin and 500 μl of dodecane mixed with the internal 
standard, hexadecane (68 μg/ml of medium), grown in a shaking incubator at 250 
rpm at 37°C for 48 hours. Two flasks were removed from the incubator at each 
sampling point (20, 30 and 48 hours after IPTG induction); the cultures were 
centrifuged at 4000 rpm for 10 minutes, the upper dodecane layer was isolated from 
the medium and used for the GCMS analysis. The cell pellet was washed once with 
water and freeze dried to determine the cell dry weight. The same procedure was 
applied to S. cerevisiae and X. dendrorhous, as well. 
 
Construction of the S. cerevisiae strain ScCop6 and time course 
analysis 
pHis8Cop6 was used as a template for the amplification of the gene to be 
cloned in the p426GPD episomal vector for the expression of Cop6 in S. cerevisiae. 
The gene was amplified with primers flanked with the restriction sites for EcoRI and 
SpeI and was mutated in positions 497 and 558 to eliminate the native EcoRI sites. 
The fragment was then cloned in the previously digested vector and the complete 
construct was used to transform the S. cerevisiae wild type strain to obtain ScCop6. 






Positive colonies were selected on plates containing minimal medium without uracil 
and one positive colony was isolated and used for the time courses.  
Similarly to the time course performed for EcCop6, eight 100-ml flasks with 10 
ml medium and 500 μl of dodecane and hexadecane solution were incubated at 30°C 
at 200 rpm. The four time points were chosen 24, 48, 72 and 96 hours from the 
inoculation in the fresh medium and the initial OD600 of the fresh cultures was 0.05 
for all the experiments. 
Isolation and characterization of X. dendrorhous mutants  
The plasmids pCrtE-PSS, pCrtYB-PSS and pPR-PSS [170] were used as 
backbone for the creation of the new plasmids pCrtE-Cop6, pCrtYB-Cop6 and pPR-
Cop6, respectively. Cop6 was amplified from the mutated gene used for the 
expression in S. cerevisiae and was flanked by the restriction sites for NheI and SalI. 
The fragment was then cloned in the digested vectors and used for the 
transformation of X. dendrorhous. The positive colonies were isolated for the ability 
to grow on selective medium with geneticin. From the transformations with pCrtE-
Cop6, pCrtYB-Cop6 and pPR-Cop6, the three new mutant strains E-Cop6, YB-
Cop6 and XdCop6 were obtained, respectively (Fig. 2). The three strains were grown 
at 21°C at 200 rpm for the analysis of production of -cuprenene in time following 
the same conditions used for the time course for ScCop6.  
 
GC-MS analysis  
The dodecane solutions isolated from the different cultures at different time 
points were diluted 1:10 in ethyl acetate and run on GCMS to reveal and quantify the 
-cuprenene production. A Shimadzu GCMS-QP5000 provided with a ZB-1ms 
dimethylpolysiloxane column (Phenomenex 0.25 mm inner diameter, 0.25 μm 
thickness, 15 m length) was used for the analysis. Two microliters of diluted 
dodecane were injected splitless and analyzed in total ion scan using helium as 
carrier gas. The GCMS program consisted of an oven initial temperature of 50°C with 
an increment of 5°C/min up to 105°C and then up to 200°C with an increase of 30°C/ 
min. The quantitation of the -cuprenene was based on the hexadecane peak which 
























Microscopy analysis and cell counting 
Aliquots of ScCop6 and XdCop6 cultures were taken after 96 hours of growth, 
diluted to OD600 0.15, approximately, and were then transferred to a Bürker counting 
chamber (Bright line, Labor Optik). The number of cells counted in a surface of 
0.0025 mm2 was multiplied by 104 and divided by the OD6600 values of the cultures 
to obtain the number of cells per OD600 unit. 
A Leica DM 6000B microscope provided with a 40x magnification objective 
and the LAS AF program was used for the visualization and to measure the size of the 
cells with the 10 μm bar provided by the LAS AF program. 
 
Acknowledgements 
The authors wish to thank Prof. Claudia Schmidt-Dannert and Grayson 
Wawrzyn from University of Minnesota for providing the genes from Coprinus 












Figure S1. GCMS chromatograms obtained from X. dendrorhous wild type strain and mutant 
strain expressing Cop4. The pink line corresponds to WT, while the black line represents the 
Cop4 mutant. The letters describe the peaks that differ between the two strains and that could 
be identified. 
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Figure 5. Fragmentation patterns and structures. (A) -cubebene; (B) -copaene; (C) 













PRODUCTION OF LAGOPODIN INTERMEDIATES 





















Xanthophyllomyces dendrorhous is a red yeast belonging to the 
Basidiomycetes phylum; its pigmentation is given by the naturally produced 
carotenoid astaxanthin [150]. The yeast has been studied mainly for its ability to 
produce this tetraterpene structure which has in 2007 reached a market size of $219 
million and expected to reach $253 million in 2015. Transformation protocols have 
been optimized and vectors have been designed to allow the overexpression or 
knocking out of genes involved in the carotenoid or in alternative pathways [118, 121, 
137, 142]. 
Combining and implementing the knowledge about the molecular biology 
with the genetic engineering tools available for the transformation of the yeast, we 
have recently demonstrated that X. dendrorhous can be used for the expression of 
heterologous terpene synthases and for the production of non-native sesquiterpenes 
[170] (Chapter 4 of this thesis). The X. dendrorhous mutant strains have shown to 
be able to produce pentalenene, cubebol and -cuprenene, although in different 
amounts.  
Pentalenene is the first committed precursor in the biosynthesis of 
pentalenolactone; this pathway encompasses 19 steps catalyzed by as many proteins, 
whose genetic sequences from Streptomyces avermitilis have been identified and 
published [161, 173]. Unfortunately, the amount of pentalenene produced in the X. 
dendrorhous transformants is low, probably due to limited protein efficiency and a 
low gene copy number. On the other hand, the production of -cuprenene in our 
yeast could reach 80 mg/L of medium in non-baffled shake flasks without optimizing 
the medium or the growth conditions. Furthermore, the steps dividing -cuprenene 
from the final drug lagopodin are believed to be restricted to a few enzymatic steps 
catalyzed by the two cytochromes COX1 and COX2, identified in Coprinus cinereus 
[162]. Thus, since the yeast can accumulate a higher content of the direct precursor 
and the number of steps involved in the biosynthesis of the final compound is 
limited, we decided to express the gene coding for the -cuprenene synthase (Cop6) 
together with the two cytochromes, COX1 and COX2, in X. dendrorhous. 
The number of genes we could express in the red yeast with the vector we 
designed and used in the past was limited to one plus the marker gene for the 
resistance against geneticin. In order to be able to clone more than one gene, a new 
vector was engineered and the genes expressed in different combinations. 






In this study, we demonstrate that X. dendrorhous can efficiently express 
and regenerate the two cytochromes producing diverse intermediates from the 
lagopodin pathway. 
 
Materials and methods 
Strains and media 
The bacterial strain E. coli XL1 blue was used to perform all the cloning 
steps; bacteria were grown at 37°C, 250 rpm in LB (10 g/L Trypton, 5 g/L Yeast 
Extract and 10 g/L NaCl). Ampicillin was used for the selection of the transformed 
colonies at a concentration of 100 mg/ml.  
The wild type X. dendrorhous strain CBS 6938 was used for all 
transformations and as negative control. The yeast was grown at 21°C in a shaking 
incubator at 180 rpm; the medium chosen for all experiments was YPD (10 g/L Yeast 
Extract, 20 g/L Peptone and 20 g/L Glucose) with 40 mg/L geneticin (G-418 Sulfate, 
Gibco) for the selection and growth of the mutant strains. 
 
Engineering of the new resistance and expression cassettes 
The resistance cassette against geneticin was amplified from the previously 
engineered vector, pCrtE [170] with the primers F1 and R1, which allowed the 
insertion of the ClaI restriction site between the BamHI site and the beginning of the 
promoter. The fragment was digested with BamHI and ligated in the vector already 
containing the crtE sequence previously cleaved with the same restriction enzyme. 
The expression module was amplified with the oligonucleotides F2 and R2 
which harbored the restriction sites for ClaI and NarI, respectively. These two 
restriction sites were chosen because of their compatible ends; furthermore, once the 
fragment cleaved with ClaI is ligated to the one with the NarI “sticky end”, a non-
palindromic sequence is created which cannot be cut again. The expression cassette 
was ligated in the pGEMT® vector from Promega and digested with NheI and XhoI to 
allow the cloning of the genes. The Cop6 gene, which had already been expressed in 









sequences for the COX1 and COX2 genes were cordially provided by Prof. Claudia 
Schmidt-Dannert from University of Minnesota. While COX1 presented only one 
sequence recognized by BamHI, COX2 included one site for BamHI, two sites for 
EcoRI and one for ClaI. Silent mutations were created by means of overlapping PCR 
steps to replace the restriction sites. 
COX1 was amplified with primers F3 and R3 which share the same 
restriction sites with primers F4 and R4, which were used to amplify COX2. Both 
reverse primers have the sequence recognized by SalI, which cleaves the DNA 
fragments leaving a compatible end with XhoI. When all the three genes were cloned 
in the expression vectors, the modules were excised from the vector by digestion with 
ClaI and NarI. The Cop6 module was ligated first in the vector with crtE and the 
resistance cassette, then in two separate reactions the COX1 and COX2 cassettes were 
inserted in the newly created vector which included also the Cop6 gene. The 
construct with the Cop6 and the COX1 cassettes was digested with ClaI and the COX2 
module was ligated to obtain a construct with all three genes from C. cinereus. 
Prior to transformation into the wild type X. dendrorhous strains, all the 
constructs were digested with EcoRI to create a fragment that could recombine with 
the genomic DNA of the yeast in correspondence of the crtE gene resulting at the 
same time in the integration of the exogenous DNA and the deletion by insertion of 
the native gene in the genome. 
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GC-MS analysis of dodecane extracts  
Dodecane was added to the yeast cultures to absorb the volatile apolar 
compounds produced by the cells before they could be released in the headspace of 
the flasks. The dodecane was isolated from the medium and the cells by centrifuging 
the culture for 15 minutes at 3000 x g; the upper layer was then removed and diluted 






1:10 in ethyl acetate. Two microliters of the diluted dodecane extract were injected 
splitless and analyzed in total ion scan using a ZB-1ms dimethylpolysiloxane column 
(Phenomenex 0.25 mm inner diameter, 0.25 μm thickness, 15 m length) on a 
Shimadzu GCMS-QP5000. The injector temperature was 275°C; the oven initial 
temperature was 50°C with an increment of 5°C/min up to 105°C and then up to 
200°C with an increase of 30°C/ min.  
 
Results and Discussion 
Engineering of a new vector for the expression of multiple genes in X. 
dendrorhous 
Since new mutant strains were needed that could express more than just the 
resistance marker and one heterologous gene, a new transformation vector was 
designed to obtain such mutants. The new strategy allows the basic expression 
modules (Fig. 1) to be assembled sequentially in a vector together with the marker 
cassette inside the sequence used for the recombination.  
As a first step, the G418 resistance module was inserted in the middle of the 
crtE gene but, differently from the original construct [170], a recognition site for the 
enzyme ClaI was inserted between the already present BamHI site and the beginning 
of the promoter (Fig. 2 A); this vector was renamed pCrtE. The presence of the two 
BamHI restriction sites at the two ends of the construct would allow the excision of 
the complete fragment including expression and resistance cassettes to be ligated in 
another recombination sequence without further modifications to the constructs. 
The restriction sites flanking the expression module were substituted by ClaI, 
before the promoter, and NarI, at the end of the GPD terminator sequence. The 
Cop6, COX1 and COX2 genes were ligated each in a single expression cassette to 
obtain the constructs Cop6cst, COX1cst and COX2cst (Fig.1). All the constructs were 






















Figure 1. Main modules for the engineering of the vectors used for the transformation of X. 
dendrorhous. GPD Prom, GPD promoter sequence; nptII, resistance gene for geneticin; 
GPD Ter, GPD terminator sequence; G418 R, resistance cassette; Cop6 cst, Cop6 
















Figure 2. Transformation constructs. (A), pCrtE (~6,800 bp); (B), pCop6 (~8,500 bp); (C), 





























pCrtE was used as the starting vector for the building up of the subsequent 
constructs; the Cop6cst was inserted upstream of the marker cassette resulting in the 
pCop6 (Fig. 2 B). pCOX1 and pCOX2 were obtained by ligating the cassettes 
COX1cst and COX2cst, respectively, in the pCop6 vector (Fig. 2 C, D). In order to be 
able to express all three genes involved in the lagopodin pathway, we ligated all the 
modules in one large construct that was named pCOX1COX2 (Fig 2 E). 
Expression of Cop6 and COX1 in X. dendrorhous mutant E-
COX1 
When the wild type strain of X. dendrorhous was transformed with the 
fragment obtained digesting the vector pCop6 with EcoRI, only white colonies (E-
Cop6) grew on the selective medium. The white phenotype of the cells indicated that 
the knock-out of the crtE gene had happened as efficiently as with the old vector used 
for previous transformations. 
The new mutant E-COX1, result of the transformation of X. dendrorhous 
with pCOX1, and E-Cop6 were grown in presence of dodecane and the 












Figure 3. GCMS chromatograms obtained from E-Cop6 and E-COX1. The pink line 
corresponds to E-Cop6, while the black line represents E-COX1. The numbers mark the 
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The peak indicated with the number 1 represents the cuprenene, and it is 
present both in the strain expressing only the Cop6 gene and in the mutant 
expressing also the COX1. This peak has a smaller area in the E-COX1 compared to 
the E-Cop6. Three new peaks appear in the E-COX1 mutant, and their 
fragmentation patterns are represented in Figure 4 together with their possible 















Figure 4. Fragmentation patterns of the peaks visible in figure 3. The numbers next to each 
graph relate the pattern with the corresponding peak in the chromatogram. For 2 and 3 also 
the possible structures are shown. 
 
The presence of these new molecules demonstrates that both genes are 
expressed and that the cuprenene is modified by the COX1 protein.  
When the same two genes were expressed in S. cerevisiae, three new peaks 
were obtained by the modifications on cuprenene by the action of COX1; one of these 
peaks has been identified as cuparene, the ring-oxidized product of cuprenene [162]. 
While cuparene does not appear in the chromatogram obtained by E-COX1, the 
fragmentation pattern of the peak number 1 might represent the derivative of the 
cuparene which has undergone a hydroxylation on the pentane ring. Furthermore, 
peak number 3 matches the pattern corresponding to the product likely representing 





















the derivative of the cuprenene with a hydroxyl group on the pentane ring. We could 
not find the cuprenene metabolite with the hydroxyl group on the pentane ring 
further oxidized to a ketone but we obtained an additional peak, number 4, which, 
unfortunately, could not identify. We speculate, from the presence of the parent ion 
at an m/z of 218, it might be a side product where the ketone group is on a different 
position on the pentane ring. Nevertheless, it appears that COX1 is responsible for 
the oxidations taking place on the pentane ring of the cuprenene molecule. 
 
Expression of Cop6 and COX2 in X. dendrorhous mutant E-
COX2 
The mutant E-COX2 was selected after the transformation with the pCOX2 
fragment, and it presented a white phenotype like all the previous mutants. Once 
more the dodecane was isolated after culturing the mutant, and the chromatogram 












Figure 5. GCMS chromatograms obtained from E-Cop6 and E-COX2. The pink line 









































The cuprenene peak in the strain expressing both Cop6 and COX2 was also 
reduced in size compared to the E-Cop6 mutant, and two new peaks appeared in 
the chromatogram. The fragmentation pattern coming from peak number 6 (Fig. 6) 
was compared to the patterns obtained when Cop6 and COX2 were expressed in S. 













Figure 6. Fragmentation patterns of the peaks visible in figure 5. The numbers next to each 
graph relate the pattern with the corresponding peak in the chromatogram, and the possible 
structures are shown. 
 
Surprisingly, the fragments of peak number 5 match those of the compound 
that Agger and colleagues found to be produced in S. cerevisiae when both COX1 and 
COX2 were expressed. While they propose that the molecule is cuparophenol with a 
ketone moiety on the pentane ring, from the mass of the parent ion and the 
fragmentation pattern of the daughter ions, we speculate it might be the quinone 
product shown in Figure 6. Our hypothesis is supported by the fact that no peak 
corresponding to a double hydroxylated cuparene is visible in the chromatogram, and 
this might be explained by its immediate conversion to the more stable quinone 
derivative. The presence of the cuparophenol and its corresponding quinone in the 
cultures implies that COX2 is responsible for the modifications on the 

























methylcyclohexadiene ring of the cuprenene towards the lagopodin A structure. Only 
a higher scale expression of the yeast and a more accurate analysis on GC or HPLC 
coupled to a high resolution mass spectrometer would provide us with more 
information on all the structures obtained from the cultures of the two mutants.  
 
Combined expression of Cop6, COX1 and COX2 in X. dendrorhous 
The vector pCOX1COX2 was used to obtain the mutant E-COX1COX2 
which could express four genes at the same time. The mutant was grown in the 
medium with dodecane. Figure 7 represents the chromatogram obtained from this 














Figure 7. GCMS chromatograms obtained from E-Cop6 and E-COX1COX2. The pink line 
corresponds to E-Cop6, while the black line represents E-COX1COX2. The chromatogram 











As in all the previous mutants, the peak corresponding to cuprenene was 
smaller than the one in the E-Cop6, confirming that the gene was expressed, the 
protein was active and the compound was modified to one or more metabolites. From 
the decrease in cuprenene concentration we would have expected one or more peaks 
appearing that could explain the lower concentration of the metabolite but we could 
only identify a small peak with a fragmentation pattern matching the one from peak 4 
in Figure 3. The presence of this peak confirmed that also the COX1 protein was 
active. 
Since no other peak was visible from the dodecane extract, we analyzed the 
medium we had previously isolated from the dodecane and the yeast cells. 
Bottom and Siehr discovered that alkaline aqueous solutions containing 
hydroxylagopodin would exhibit a purple coloration [174]. These findings suggest 
that a shift in the color of the medium from the E-COX1COX2 mutant towards a 
purple hue should be visible if hydroxylagopodin is produced by the yeast. In order to 
evaluate whether this was the case, NaOH was added to the medium extracted from 
the cultures of all the mutants. While the medium in which E-Cop6 had grown did 
not present any color change, the media from E-COX1 and E-COX2 turned red. A 
purple shade of color was visible for the growth broth in which E-COX1COX2 had 
grown, showing that hydroxylagopodin or a similar compound was likely to be found 
in the solution. Unfortunately, this coloration was observed only in one occasion with 
only 10 ml of media and after the vials had been stored at 4°C, and even after 
extraction of the media with ethyl acetate and analysis on TLC plates, we could not 
isolate nor identify the compounds produced by the mutant E-COX1COX2. 
Bu’Lock and Darbyshire studied the stability of the lagopodin metabolites in 
alkaline water solution and discovered them to be highly unstable at neutral or 
slightly basic pH already after 6 hours [175]. This high instability might explain why 
we were not able to isolate the compounds from cultures with higher volumes, since 
for the yeast it would take at least 3 days to be able to accumulate large enough 
concentrations of the metabolite to be visible on TLC plates. 
In conclusion, we have designed and tested a new cloning strategy that allows 
transformation of X. dendrorhous with a series of genes without need for several 
selection markers. This new vector permitted us to obtain mutant strains of X. 
dendrorhous that could express a complete pathway towards the production of a new 
non-native metabolite. The vector is indispensable in the process towards the 






utilization of the red yeast as a production organism for compounds obtainable after 
several modifications catalyzed by different enzymes. 
The X. dendrorhous mutant expressing three genes from the lagopodin 
pathway produced a purple pigment that is likely a metabolite of lagopodin although 
no isolation or identification was possible. A solution to the isolation problem lies in 
the use of buffered medium where the pH could be kept acidic enough to avoid 
degradation of the compounds. Once the compound is isolated, it could be subjected 
to NMR or High resolution mass spectrometry for the structure elucidation and its 
activity as a promising new antibiotic could be evaluated. Furthermore, we have 
demonstrated that there is no need to express additional reductases for the 
regeneration of the cytochromes since the one already present in X. dendrorhous 
could function also on the heterologous cytochromes COX1 and COX2. This 
observation is important since cytochromes are involved in several terpene 
backbones modification steps toward finished drugs, like artemisinin and paclitaxel 
[84, 176], and an organism like X. dendrorhous that can provide regeneration of the 











ORGANELLAR TARGETING OF AMORPHADIENE 

















Saccharomyces cerevisiae has been used since ancient times as a 
fermentation microorganism and has more recently become the model organism for 
studies on eukaryotic cells [177]. With the development of genetic engineering S. 
cerevisiae has been used for the production of several diverse compounds, ranging 
from biofuels to flavors to drugs [101, 178-183]. In particular, studies on the 
production of terpene-based drugs have represented an effective approach combining 
synthetic biology and metabolic engineering [145]. One of the most successful results 
was obtained with amorphadiene, the first committed precursor of the antimalarial 
terpenoid drug artemisinin [89]. After multiple studies following various approaches 
[69, 70, 84], a single strain of S. cerevisiae was engineered and optimally cultured to 
obtain an unprecedented 40 g of amorphadiene per liter of yeast culture. The step-
by-step engineering of such a strain unveils the potential of metabolic engineering as 
one of the successful fields in the struggle to obtain cheaper drugs. 
Most of the research involving the accumulation of terpenoid drugs in S. 
cerevisiae has focused on precursors present in the cytosolic environment of the cell. 
In plants, terpene structures can be produced in different compartments in the cell, 
mostly plastids, mitochondria and endoplasmic reticulum [184]. Recently, though, 
isoforms of enzymes involved in the terpenoid pathway have been identified also in 
the peroxisomes of Arabidopsis thaliana and Catharanthus roseus [185, 186]. 
Furthermore, a mevalonate kinase, a phosphomevalonate kinase and a mevalonate 
diphosphate decarboxylase have been localized in mammalian peroxisomes and two 
geranylgeranyl diphosphate synthases (GGPS) were found to be expressed in 
Penicillium paxilli in the same compartment [187, 188]. More interestingly, the Bts1p 
gene, encoding for a GGPS in S. cerevisiae is localized in the yeast mitochondria, 
suggesting the presence of terpene building blocks in different compartments also in 
the baker’s yeast [189]. 
To confirm that terpene structures can be found in different cell organelles in 
S. cerevisiae, we have used the gene coding for amorphadiene synthase (ADS) from 
Artemisia annua and fused it to the targeting signals for the translocation of the 
proteins to mitochondria and peroxisomes. The green fluorescent protein (GFP) gene 
was also fused to the ADS in order to be able to confirm that the ADS protein was 
correctly directed to organelles. The targeting signal COX4, when fused to the N-






terminus of a protein, has been demonstrated to be sufficient for the targeting of 
proteins to the mitochondria [190].  
Most of the proteins directed towards the peroxisomes are characterized by a 
tripeptide sequence that does not get excised after translocation to these organelles. 
This short sequence, called peroxisomal targeting signal (PTS1), was discovered for 
the first time in fireflies’ proteins [191] and it was shown to be a highly conserved 
SKL (Ser-Lys-Leu) peptide at the protein C-terminal end. 
We engineered four plasmids and obtained four S. cerevisiae strains: the first 
(ScADS) expressed the native form of ADS in the cytoplasm; the second (ScGFP) 
contained the plasmid with ADS fused to GFP; the third mutant (ScCOX) was is 
equipped with the COX4 targeting sequence in order to transport the fusion protein 
ADS-GFP to the mitochondria; the fourth strain (ScPTS) is transformed with the 
plasmid containing the PTS1 targeting sequence at the 3’-end of the ADS::GFP gene. 
The strains were analyzed by confocal microscopy for presence of the green 
fluorescence, and, in parallel, the biosynthesis of amorphadiene was determined by 
GC-MS. 
 
Materials and methods 
Strains and media 
For all the cloning steps E. coli DH5 strain was used; bacteria were grown at 
37°C, 250 rpm in LB (10 g/L Trypton, 5 g/L Yeast Extract and 10 g/L NaCl). 
Ampicillin was used for the selection of the transformed colonies at a concentration 
of 100 mg/ml.  
For the transformation processes, S. cerevisiae MRG 5 #502 (MATa, ura3-
52, leu2-1, trp1-36, his3-200, Dade2) was used. The growth medium for S. 
cerevisiae consisted of 13.4 g/l Yeast Nitrogen Base without amino acids, 20 g/L 














Engineering of the constructs for the expression of ADS::GFP in 
different cell compartments 
The plasmid used for the expression of all the genes was the p426 with the 
repressible promoter Met25 for the regulation of the gene expression [192]. The 
plasmid was digested with the restriction enzymes EcoRI and SpeI for the 
unidirectional cloning of the genes. 
The ADS gene in the plasmid p426Met-ADS for the production of the ADS 
protein in the cytosol was amplified with primers F1 and R1 (Table 1). The gene was 
amplified with Phusion polymerase (New England Biolabs) and subsequently A-
tailed for the ligation in the vector pGEMT (Promega). The positive colonies were 
selected on LB plus ampicillin; 0.5 mM isopropyl -D-1-thiogalactopyranoside 
(IPTG) and 80 μg/ml 5-bromo-4-chloro-3-indolyl--D-galactoside (X-Gal) were also 
added for the blue-white colony screening. The gene was then sequenced, excised 
from the pGEMT vector with the two mentioned restriction enzymes and ligated in 
the previously digested p426Met.  
The ADS fragment to be fused to the GFP gene (codon optimized for S. 
cerevisiae [193]) was amplified with primers F1 and R2. The GFP gene was instead 
amplified with primers F2 and R3 and the fragment was used for the double step PCR 
to fuse it to ADS. Briefly, a first PCR was performed using the ADS and the GFP 
amplicons as primers and templates since they share an overlapping sequence of 30 
base pairs. After 5 cycles, the primers F1 and R3 were added to obtain the complete 
fused gene ADS::GFP. After purification and ligation in pGEMT, the product was 
digested and ligated in the shuttle vector for S. cerevisiae to create p426Met-
ADS::GFP. 
The mitochondrial COX4 targeting sequence was amplified from S. 
cerevisiae genomic DNA using oligos F3 and R4 and then fused to the ADS::GFP 
which had been amplified with the primers F4 and R3. The two-steps PCR with F3 
and R3 produced COX4-ADS::GFP that was then treated as the other fragments and 
ligated into p426Met to obtain p426Met-COX4-ADS::GFP. p426Met-ADS::GFP-PTS1 
was engineered by ligating the ADS::GFP previously amplified with primers F1 and 
R5 into p426Met. All the constructs were used to transform S. cerevisiae with the Li 
acetate method [194]. The positive colonies were selected for the ability to grow on 
minimal medium not supplemented with uracil. 
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Time course analysis 
The growth curves and the amorphadiene production of the four strains 
ScADS, ScGFP, ScCOX and ScPTS were evaluated during a time course experiment 
for 96 hours with four time points every 24 hours. A fresh overnight culture for each 
strain was used as inoculum for the main time course experiment with initial optical 
density (OD) was 0.05. The time course was conducted in 100 ml-flasks with two 
flaks for each strain and time point. Every 24 hours for 4 days, the two flasks for each 
strain were removed from the incubator at 30°C at 180 rpm and the cultures were 
centrifuged at 4000 rpm at 4° C for 15 minutes. After centrifugation a clear phase 
separation was visible between the medium and the dodecane layer. The organic 
solvent was removed from the aqueous phase and used for the subsequent GC-MS 
analysis. The pelleted cells were washed once with 1 ml of distilled water and freeze 
dried for the determination of the cell dry weight. 
 
Cell permeability and organellar specificity of LysoTracker® and 
Mitotracker® 
S. cerevisiae cells transformed with the empty vector p426Met were grown 
over night and used for the experiments with the two probes, LysoTracker® Red 
DND-99 and Mitotracker® Orange. 
The amount of cultures corresponding to an OD of 1 was centrifuged at 1000 
rpm for 10 min and resuspended in room temperature growth medium with 38 nM of 
LysoTracker® Red DND-99 (Invitrogen) or 250 nM Mitotracker® Orange 









probes at 21° C in a shaking incubator at 250 rpm for 60, 75 or 90 min. After the 
incubation time, cells were centrifuged and fixed for 2 hours in 100 mM phosphate 
buffer (pH 6.5) to which 3.7% formaldehyde had been added. Two washing steps with 
only phosphate buffer were performed and, finally, cells were resuspended in buffer, 
10 μl were pipetted on a glass slide and visualized using a confocal laser microscope. 
 
GFP expression in S. cerevisiae mutant strains 
Cells from the strains ScGFP, ScCOX and ScPTS were centrifuged and fixed 
following the same protocol as for the analysis with the two probes. A Leica DM IRE2 
Inverted microscope with Hg 50 w mercury lamp equipped with two objectives (HCX 
PL APO CS 40x/1,25 oil 0,1mm and HCX PL APO 63x/1,4 oil 0,1mm) was used to 
visualize the whole cells and the inner compartments. The excitation wavelength for 
the GFP was set at 476 nm, while the emission was recorded at 512 nm. More 




Evaluation of permeability and cellular compartmentalization of 
organelle-specific probes by confocal microscopy 
The organelle-specific probes LysoTracker® Red DND-99 and Mitotracker® 
Orange are normally used for the staining of the cellular compartments in eukaryotic 
cells with different specificity. Mitotracker® is meant for the localization and 
counting of active mitochondria after oxidation-driven fluorescence. After fixation 
with formaldehyde, the complex formed by the probe and the mitochondrial proteins 
becomes permanent and the organelles are permanently dyed. 
LysoTracker® is normally utilized for the staining of the lysosomes, as the 
probe is constituted by a fluorophore linked to a weak base and it accumulates in 
acidic organelles. Since fatty acids metabolism in yeast occurs in peroxisomes, they 
are thought to have a lower pH compared to the cytosol. The acidic pH of 
peroxisomes makes them a likely candidate for the staining with LysoTracker®. 
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In order to evaluate the permeability and the specificity of the dyes in the 
yeast cells we incubated the cells with the two probes separately and observed the 
fluorescence in the cells in time (Figure 1). 
The permeability of the probe for the lysosomes was in general poor even 
after incubation for 2 hours; furthermore no specificity for any organelles could be 
observed since the cell cytosol appeared to be completely dyed. In spite of the faster 
and more extensive cell penetration compared to LysoTracker®, also the 












Figure 1. Treatment of S. cerevisiae cells with LysoTracker® (A, B and C) or Mitotracker® (D, 
E and F). Cells were observed under microscope after 1h (A and D), 1,5 h (B and E) and 2h (C 
and F) incubation with the respective probes 
 
Isolation and growth analysis of S. cerevisiae mutants 
The four S. cerevisiae mutants were selected on medium lacking uracil; 
single colonies were isolated and used for all the subsequent analyses. ScADS, ScGFP, 
ScCOX and ScPTS were the strains obtained from the transformations of the wild 
type strain with the plasmid p426Met-ADS, p426Met-ADS::GFP, p426Met25-COX4- 
ADS::GFP and p426Met-ADS::GFP-PTS1, respectively. 
In order to evaluate differences in growth among the four strains, a time 
course was performed on all strains for four days and the dry cell weight was used as 









during the time course are plotted in Figure 2. ScADS, ScGFP and ScPTS exhibit 
similar growth curves with a fast exponential growth between the first and the second 
day of culturing. In contrast, ScCOX has a lag phase in the first 24 hours and an 


















Figure 2. Growth curves obtained with ScADS, ScGFP, ScCOX and ScPTS 
 
Expression of GFP-fusion proteins and localization in the cells 
The confocal microscope allowed us to visualize the localization of the fused 
protein ADS::GFP in the cytosol, mitochondria or peroxisomes. The advantages 
provided by a confocal microscope compared to a normal fluorescence microscope 
consist of a higher sharpness of the pictures and the possibility to observe cells lying 
on the same layer, avoiding the interference from the background fluorescence. 
After fixation in formaldehyde, the cells were transferred to a glass slide and 
observed using a fluorescent microscope. No more than 50% of the cells for all the 
constructs appeared fluorescent under the microscope (Fig. 3) and the production of 
the protein varied from cell to cell even for the same mutant strain. 
 


























Figure 3. Overlaid fluorescence and bright field photographs of S. cerevisiae mutants. (A) 
ScGFP, (B) ScCOX and (C) ScPTS 
 
The ScGFP mutant shows fluorescence throughout the whole cell, confirming 
that the expression of the protein is cytosolic and does not show any particular 
accumulation point. From the image obtained with the ScCOX strain, some defined 
spots are visible inside the cells and the protein production appears lower than in the 
cells expressing the cytosolic version of the protein. The organellar accumulation is 
even more visible in the case of the strain ScPTS (C); while a few cells still show a 
fluorescent signal in the whole cell, most of the others exhibit discrete and defined 
accumulation points in the cytosol. The number of the fluorescent spots differs from 











Amorphadiene production in S. cerevisiae mutant strains 
Concurrently with the analysis of the biomass accumulation for the four 
mutant strains, an estimation and comparison in the production of amorphadiene 
was performed by adding a dodecane layer to the cultures. The comparison in 
production among the mutants was made possible by the addition of an internal 
standard to the dodecane solution, which allowed also for normalization of the data 
after growth and isolation of the organic layer. 
In Figure 4 the quantitation of the amorphadiene production in the 













Figure 4. Amorphadiene accumulation per liter of medium in mutant strains ScADS, ScGFP, 
ScCOX and ScPTS 
 
The first clear result is the lower sesquiterpene accumulation in the ScCOX 
mutant compared to the strain with the cytosolic version of the fused protein, while 
ScPTS shows only a 10% reduction in metabolite production. 
In all four mutants the major increase in production of amorphadiene 
corresponds with the log phase of the cell mass accumulation curve: for ScADS, 






ScGFP and ScPTS this happens between 24 and 48 hours from the inoculation in the 
fresh medium, while the growth boost in ScCOX is delayed of one day compared to 
the other mutants. 
In order to evaluate whether the reduced cell mass of the mitochondrial 
mutant affects the amorphadiene accumulation, the terpene production values were 













Figure 5. Production of amorphadiene in ScADS, ScGFP, ScCOX and ScPTS normalized for 
the cell dry weight. 
 
The decreased accumulation of amorphadiene in ScCOX compared to ScADS 
is independent of the lower cell mass of the first mutant; the same conclusion can be 
drawn for the strain with the peroxisome-targeted protein. Furthermore, the fusion 















The limited concentration of artemisinin in A. annua plants and the 
previously discovered complicated and expensive total chemical synthesis of the 
compound have made the sesquiterpene lactone one of the pharmaceuticals with a 
high market demand but low availability. In order to overcome the supply problems 
for the antimalarial drug, research groups have developed a new synthetic route 
which reduces the costs of production [195] and an improved S. cerevisiae strain as 
cell factory with an unprecedented titer of amorphadiene [89].  
In our study we evaluate what is the potential for amorphadiene production 
in cell organelles in S. cerevisiae. We chose to express for the first time the ADS gene 
fused to a variant of GFP from the jellyfish Aequorea victoria codon optimized for S. 
cerevisiae. A short linker was used to allow both proteins to fold correctly. For the 
translocation of the protein to the peroxisomes or to the mitochondria, we created 
two constructs in which the ADS::GFP gene was fused to the targeting signal 
sequences COX4 or PTS1.  
The localization in the cells of the fluorescent proteins was visualized by a 
confocal microscope which allowed high resolution pictures of cells. Single luminous 
spots were visible in the mutants ScCOX and ScPTS, while a widespread 
luminescence in the cells was a characteristic of the strain expressing the cytosolic 
protein. In order to confirm that the targeted organelles were in fact the expected 
ones, we tested two organelle-specific probes. Unfortunately, we could not obtain a 
specific accumulation of the dyes in the expected compartment since the cells were 
poorly colored and/or the fluorescence was spread throughout the whole cell. 
The fusion of the GFP protein to ADS resulted in a 20% reduced 
amorphadiene production in the cytosol which might be caused by a decrease in 
activity of the ADS protein or by a reduced expression of the gene. 
In contrast with the results obtained by Farhi and colleagues [196], we 
observed an affected growth and reduced production of amorphadiene when the 
ADS::GFP gene was fused to the targeting signal for the mitochondria. This 
discrepancy in the results might be explained by a few factors: the presence of the 
GFP might affect the ADS protein reducing its activity in the mitochondrial 
environment; while we have used a constitutive promoter regulating the gene 
expression and we opted for an episomal plasmid, Farhi and colleagues used an 
integrative construct with a copper induced promoter. In spite of these conflicting 






outcomes, it is reasonable to expect an affected growth in a strain which is depleted 
of an important precursor such as FPP in the energy factory of the cell.  
For the first time we have shown that the fusion protein ADS::GFP can be 
transported to the peroxisomes and that both activities, fluorescence and 
amorphadiene synthesis, are functional in these organelles. The formation of 
amorphadiene demonstrates that peroxisomes contain FPP that can be converted by 
ADS. 
In spite of the lower production of amorphadiene in ScCOX and ScPTS 
compared to the strain with the cytosolic variant of the ADS protein, the opportunity 































The class of natural compounds known as terpenes, terpenoids or 
isoprenoids includes nearly 25,000 structures. Terpenes are produced by eukaryotes 
and prokaryotes alike, and they assume a wide variety of functions. Carotenoids 
(possessing antioxidant properties), limonene and menthol used by cosmetic and 
food industries, paclitaxel used to treat cancer patients and artemisinin used to treat 
malaria; all these compounds share a basic terpene skeleton modified subsequently 
by cytochromes and other structure decorating enzymes. 
Terpenes are produced via two routes, the MEV and MEP pathway. Although 
these pathways start with different substrates, both produce isopentenyl diphosphate 
(IPP) and dimethylallyl diphosphate (DMAPP). These two building blocks are then 
fused to create larger structures that represent the backbone of all terpenes. While 
fungi and animals possess the MEV pathway and prokaryotes the MEP pathway, 
plants can produce terpenes via both routes. Furthermore, in plants the two 
pathways are confined into different cell compartments. 
Some pharmaceutically important terpene derived drugs, like artemisinin 
and paclitaxel (Taxol®), are produced in low concentrations in their native hosts (the 
plant Artemisia annua for artemisinin and the Taxus spp. tree for paclitaxel). Often 
organic synthesis of these compounds is costly; the extraction from the natural 
sources can put the original species in extinction danger and the amounts of isolated 
compounds cannot fully cover the market demand. Genetic engineering has helped 
consistently in the fight for cost efficient and sufficiently available terpene drugs. 
Parts of the biosynthetic routes for some of the compounds have been elucidated and 
the enzymes have been transferred to heterologous hosts in order to obtain higher 
yields than the ones from the native hosts. One of the successful examples is the 
production of the precursor of artemisinin, amorphadiene, reaching 40 g/L of 
Saccharomyces cerevisiae culture. Metabolic engineering has majorly contributed to 
this achievement, allowing the fine tuning of the genes involved in bottleneck steps 
with the aim of increasing the flux of precursors towards the desired product. 
An organism metabolically optimized towards the highest production of a 
class of compounds is called a “platform organism”, while an organism optimized to 
yield a single product is named a “cell factory”. For the terpenes class, the two likely 
candidates, i.e. on which most of the research groups have focused, are Escherichia 
coli and S. cerevisiae. Both microbes have been extensively studied and adapted to 
produce a wide range of compounds, including proteins, drugs and biofuels. Despite 






the big successes obtained with these two organisms, biodiversity can still provide 
alternative organisms which might be even better platform organisms, but that have 
not been fully studied, yet.  
The research in this thesis aims at evaluating the potential as terpene cell 
factory of Xanthophyllomyces dendrorhous, the yeast producing the carotenoid 
astaxanthin which gives the characteristic red color to the yeast. The ability of X. 
dendrorhous to accumulate carotenoids can be exploited for the production of 
diverse terpene compounds by transferring heterologous genes from interesting 
biosynthetic routes to the genome of the yeast.  
This thesis describes the engineering of special vectors for the transformation 
of the yeast and the analysis of the metabolites produced by X. dendrorhous mutants. 
Furthermore, the last chapter studies the potential of organellar targeting of the 
amorphadiene synthase gene in S. cerevisiae mutant strains. 
 
X. dendrorhous: a potential platform organism for terpenes 
X. dendrorhous has been explored for astaxanthin production since the 
isolation of the yeast in the 1970s. Recently, with the elucidation of parts of the 
pathway towards carotenoids and with the increase in market size of “natural” 
compounds with antioxidant properties, the efforts put in transforming the red yeast 
into a cell factory for the production of astaxanthin have increased substantially. 
Some research groups have focused on looking for natural astaxanthin high-
producing strains while others have relied on genetic engineering and have designed 
vectors and transformation protocols to obtain new strains overexpressing crucial 
genes in the terpene and carotenoid pathways. These studies have provided us with 
the necessary sequences that have allowed us to modify the vectors for our research 
purposes.  
Chapter 3 presents the main concept behind the work described throughout 
this thesis: when heterologous terpene synthases are transferred to X. dendrorhous 
mutants, non-native terpenes can be produced by the new strains in which the 
astaxanthin pathway has been knocked out. We designed a vector which allows the 
concomitant integration of an expression cassette and the knock out (by insertion) of 
one of the genes involved in the carotenoid pathway. The GGPP synthase and the 









transferred to X. dendrorhous was the pentalenene synthase, which uses FPP as 
substrate and produces pentalenene, the precursor of the antibiotic pentalenolactone. 
Yeast strains expressing this synthase produce pentalenene and do not show any 
growth alterations, except for the white phenotype denoting a complete lack of 
astaxanthin production. The highest concentration of the sesquiterpene pentalenene 
was obtained in the red strain in which the vector had integrated in the rDNA 
sequences in the genome, rather than in the previously mentioned genes. This higher 
accumulation might be explained by multiple integrations of the expression cassette 
in several rDNA sequences spread throughout the whole genome.  
After proving that the strategy for the transformation of X. dendrorhous was 
successful, we decided to evaluate efficiency of the sesquiterpene production of our 
yeast. For this reason, as described in Chapter 4, we transformed the red yeast, E. 
coli and S. cerevisiae with the Cop6 gene isolated from the basidiomycetes Coprinus 
cinereus. All X. dendrorhous strains accumulate -cuprenene, the metabolite 
produced by Cop6, in higher concentrations than E. coli and S. cerevisiae, confirming 
our idea that the red yeast possesses a high potential for the production of terpenes. 
Furthermore, X. dendrorhous is cultured at temperatures ranging from 20 to 24°C 
and it grows better on minimal medium compared to S. cerevisiae, making the red 
yeast a possible alternative as industrial strain for the production of terpenes. 
 
Most of the terpene drugs are constructed via multistep pathways involving 
several enzymatic modifications. The results presented in Chapter 5 were obtained 
when two cytochromes involved in the pathway towards lagopodin A were expressed 
in combination with the Cop6 gene in X. dendrorhous. In C. cinereus -cuprenene is 
the first committed precursor of lagopodin A, but it requires a few oxidation steps to 
give the final antibiotic drug. Two cytochromes, COX1 and COX2, have been found 
flanking the Cop6 gene in the fungus, and, since genes involved in the same pathway 
are often clustered together in the genome, these two proteins are presumably 
involved in the oxidation of -cuprenene to lagopodin A. 
In order to be able to express Cop6, COX1 and COX2 in the same X. 
dendrorhous strain, we engineered our vector with a new expression cassette that 
could be assembled together with, in principle, an infinite number of this cassette, 
expressing the same or alternative genes. This new vector allowed us to express the 
three genes in X. dendrorhous and confirm their involvement in the lagopodin A 






biosynthesis. Intermediates from the lagopodin A pathway were identified when the 
three genes were expressed in X. dendrorhous, albeit no lagopodin A could be 
isolated. Nevertheless, when the growth medium was alkalinized, a purple coloration 
appeared revealing the likely presence of the antibiotic drug or a closely related 
compound which can turn violet in aqueous alkaline solutions. Notably, the 
regeneration of the cytochromes, which is normally performed by a reductase, was 
attained by one or more native reductases from X. dendrorhous, eliminating the 
necessity to transfer additional genes to the yeast strain. 
 
Expression of amorphadiene synthase in Saccharomyces 
cerevisiae cell compartments 
Amorphadiene synthase (ADS) is the enzyme that performs the cyclization of 
FPP to give amorphadiene, the first committed precursor in the artemisinin pathway 
in Artemisia annua. This protein has been expressed in several organisms, including 
E. coli, S. cerevisiae, Nicotiana tabacum and Aspergillus niger. The research on the 
production of artemisinin and amorphadiene has been extensive since this 
antimalarial drug is produced in too low levels to cover the market demand. Genetic 
engineering of S. cerevisiae has allowed the production of amorphadiene in this 
yeast. This molecule can then be converted, by chemical synthesis, into artemisinin. 
The ADS protein has been targeted to the cytosol of the yeast cells; however, several 
organisms produce terpene precursors in other cellular compartments, including 
mitochondria and peroxisomes.  
The targeting sequences for these two organelles in yeast were fused to the 
ADS gene and expressed in S. cerevisiae (Chapter 6). In order to be able to confirm 
that the proteins were transported to the compartments, a yeast-optimized version of 
the green fluorescent protein (GFP) was fused to the ADS constructs. While the 
fluorescence was widely spread throughout the cytosol in the strain with the 
untargeted ADS-GFP fusion protein, isolated spots were visible in the cells of the 
strains with the peroxisomal and with the mitochondrial versions of the protein. The 
strain that translocated the protein to the mitochondria was affected in growth, 
showing a longer lag phase, while no growth rate modification was registered for the 
strain with the peroxisomal version of the protein. The activity of ADS was slightly 









indicating that the yeast accumulates FPP in both types of organelles. Even though 
the production of amorphadiene in mitochondria and peroxisomes was lower than in 
the cytosol, this shows that there is an untapped pool of terpenes precursors that can 
still be used to produce more amorphadiene in yeast. 
 
X. dendrorhous has shown to be able to produce non-native sesquiterpenes 
without being affected in growth. Notably, the metabolites are produced in different 
concentrations, revealing that the accumulation levels were not depending on the 
concentration of the precursor FPP, but, instead, on the activity of the proteins. This 
observation is confirmed by the similar amounts of pentalenene or -cuprenene 
accumulated in the strains knocked-out in the carotenoid pathway and in the 
mutants still producing astaxanthin. The yeast mutants can support production, at 
the same time, of astaxanthin and additional sesquiterpenes, showing that the yeast 
holds the potential for the accumulation of even higher quantities of terpene 
metabolites. We propose that an increased number of gene copies in the mutants 
could improve the sesquiterpene levels and provide a valid alternative to the strains 
used in industry for the production of terpenes.  
We have expressed a limited number of genes in X. dendrorhous but now, 
with the development of our new, easy to modify and efficient vector for the 
transformation of the yeast, we have definitively shortened the time necessary to 
obtain new mutants. Furthermore, the possibility of expressing a virtually unlimited 
number of genes in a single strain will speed up the research to find the best terpene 
platform organism. 
Very little is known about the molecular biology of X. dendrorhous and only 
a limited number of gene sequences are available. The sequencing of the genome of 
the red yeast would provide us with the knowledge to develop far more powerful tools 
than the ones we possess at the moment; with a higher number of known gene 
sequences, a reliable codon usage could be identified and heterologous genes could 
be codon optimized to improve their translation efficiency and activity in the cells. 
Stronger promoters could be used to increase the expression of genes resulting in 
higher yields of metabolites. Organellar targeting of terpene synthases could also be 
explored in X. dendrorhous using, as a starting point, the experiments performed for 
the translocation of ADS in peroxisomes or mitochondria of S. cerevisiae cells.  






Furthermore, analysis of the metabolome of the yeast could help identifying 
bottlenecks in the terpene pathway that can be relieved by the overexpression of the 
genes coding for the responsible proteins, thus increasing the downstream 
production levels of the terpenes. 
The path towards the identification and engineering of an organism that is 
capable of delivering high yields of terpene drugs is still long, and it necessitates 
inputs from several disciplines to progress further. However, we are convinced that 
we have proven that X. dendrorhous is a starting point for the development of a new 
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De klasse natuurproducten die bekend staat onder de namen terpenen, 
terpenoïden en isoprenoïden omvat bijna 25.000 chemische structuren. Terpenen 
worden geproduceerd door eukariotische en prokariotische organismen, en hebben 
een scala aan biologische functies. Verschillende belangrijke stoffen — carotenoïden 
(als antioxidanten), limoneen en menthol worden gebruikt in de cosmetische en 
voedingsindustrie, en paclitaxel (Taxol®) en artemisinine worden gebruikt om 
patiënten te behandelen tegen respectievelijk kanker en malaria — hebben een 
terpeen basisstructuur en worden gevormd vanuit deze structuur via verdere 
functionalisatie door cytochromen en andere enzymen. 
Terpenen worden geproduceerd via de mevalonaat (MEV) óf de 
methylerythritol fosfaat (MEP) route. Deze routes gebruiken verschillende stoffen als 
startpunt, maar vormen beide isopentenyl difosfaat (IPP) en dimethylallyl difosfaat 
(DMAPP). Door combinatie van deze twee bouwstenen worden dan grotere, meer 
complexe, structuren gevormd die als basisstructuur dienen voor alle terpenen. 
Planten zijn speciaal aangezien zij beide routes kunnen gebruiken. Schimmels en 
dieren kunnen alleen de MEV route gebruiken en prokarioten alleen de MEP route. 
In planten vinden de routes wel plaats in verschillende celcompartimenten. 
Sommige terpeen medicijnen, zoals artemisinine en paclitaxel, worden in 
lage concentraties geproduceerd door in natuur-voorkomende organismen, 
respectievelijk de plant Artemisina annua en (sommige) Taxus spp. bomen. Vaak is 
de synthese van deze medicijnen door chemische synthese duur en moeilijk. Ook het 
winnen van deze stoffen door extractie vanuit de natuurlijke bron is af te raden, 
aangezien dit de soort met uitsterving kan bedreigen; zeker omdat deze organismen 
zonder genetische modificatie niet voldoende produceren om aan de vraag te 
voldoen. Genetische modificatie heeft er voor gezorgd dat de prijs van terpeen 
medicijnen omlaag is gegaan, en dat er genoeg van de benodigde stoffen 
geproduceerd kan worden. Door onderzoek zijn voor sommige van deze medicijnen 
delen van de biosynthese routes opgehelderd. Door deze verkregen kennis is het 
gelukt om enzymen uit deze routes in heterologe gastheren tot expressie te brengen, 
zodat in deze organismen meer van de stoffen geproduceerd kan worden dan in de 
niet-gemodificeerde organismen. Eén van de succesvolle voorbeelden is de productie 







cerevisiae cultuur (tot 40 g/L). Genetische modificatie is erg belangrijk in dit 
voorbeeld, het heeft er namelijk voor gezorgd dat de genen geoptimaliseerd  worden 
om meer “flux” van de precursors naar het beoogde product te krijgen door de 
“bottlenecks” aan te pakken. 
Een organisme waarin het metabolisme is geoptimaliseerd voor de productie 
van een bepaalde stof wordt een “cell factory” genoemd, terwijl een organisme dat 
geoptimaliseerd is om een klasse van stoffen te maken een “platform organisme” 
wordt genoemd. Om een “cell factory” voor terpenen te creëren zijn door de meeste 
onderzoeksgroepen maar twee organismen bestudeerd, namelijk Escherichia coli en 
S. cerevisiae. Beide microben zijn uitvoerig onderzocht en geoptimaliseerd om een 
scala aan stoffen te produceren, onder meer eiwitten, medicijnen en biobrandstoffen. 
Deze twee organismen zijn echter niet de enige die bestudeerd kunnen worden, en de 
biodiversiteit bevat andere organismen die meer potentie als “platform organisme” 
kunnen hebben, maar waarover nog niet genoeg bekend is. 
Het onderzoek beschreven in dit proefschrift heeft als doel om de potentie te 
bepalen van Xanthophyllomyces dendrorhous als terpeen “platform organisme”. X. 
dendrorhous staat bekend om de productie van het carotenoïde astaxanthine, dat de 
karakteristieke rode kleur aan deze gist geeft. Aangezien X. dendrorhous 
carotenoïden produceert, kan deze gist worden geëxploiteerd om andere terpenen te 
produceren door heterologe genen, die normaal gebruikt worden in interessante 
biosynthese routes, in het genoom van de gist te integreren.  
In dit proefschrift wordt het ontwerp van speciale vectors, om X. 
dendrorhous te kunnen transformeren, beschreven. Verder worden 
analysemethoden ontwikkeld om de metabolieten te kunnen identificeren, die door 
mutanten van deze gist geproduceerd worden. Verder wordt in het laatste hoofdstuk 
van dit proefschrift een studie naar de optimalisatie van de productie van 
amorphadieen door S. cerevisiae beschreven. Deze optimalisatie vindt plaats door 
het amorphadieen synthase gen in specifieke celdelen tot expressie te brengen, dit 












X. dendrorhous: een potentieel “platform organisme” om 
terpenen te produceren 
Aan het eind van de zeventiger jaren van de afgelopen eeuw werd X. 
dendrorhous geïsoleerd en sindsdien is de productie van astaxanthine in deze gist 
bestudeerd. Recent is er meer onderzoek naar het gebruik van de rode gist X. 
dendrorhous als geoptimaliseerde “cell factory” om asthaxanthine te produceren, 
aangezien delen van de biosynthese route van carotenoïden bekend zijn geworden, en 
verder omdat er tegenwoordige een grotere vraag is naar “natuurlijke” stoffen met 
antioxidante eigenschappen. Sommige onderzoeksgroepen hebben zich 
geconcentreerd op het identificeren van originele, natuurlijke stammen van deze gist 
die uit zichzelf meer asthaxanthine produceren. Andere groepen hebben geprobeerd 
om via genetische modificatie overexpressie van cruciale genen in de terpeen en 
carotenoïd biosynthese routes te bewerkstelligen, door nieuwe vectors en nieuwe 
transformatie protocollen te ontwerpen. De genetische modificatie studies hebben 
informatie opgeleverd over sequenties die nodig zijn om vectors te veranderen voor 
onze onderzoeksdoelen. 
Hoofdstuk 3 belicht het terugkerende thema van het werk beschreven in dit 
proefschrift: door genetische modificatie kunnen mutanten van X. dendrorhous 
andere terpenen dan asthaxanthine produceren die normaal niet geproduceerd 
kunnen worden door deze gist. Dit wordt mogelijk gemaakt door enzymen in de 
asthaxanthine biosynthese route uit te schakelen (zogenaamde “knock outs”), en 
terpeen synthases tot expressie te brengen. Wij hebben een vector ontworpen waarin 
én de knock out van één van de genen van de carotenoïde biosynthese route én de 
expressie cassette voor het gen van interest zijn geïntegreerd. Als de plaats waar het 
nieuwe gen in het genoom wordt ingebracht (de zogenaamde recombinatie 
sequenties) zijn de GGPP synthase en phytoeen synthase genen geselecteerd. Het 
eerste gen dat naar X. dendrorhous werd overgezet is het pentaleneen synthase, dat 
FPP als substraat gebruikt om pentaleneen te produceren. Pentaleneen is de 
precursor van het antibioticum pentalenolacton. De gist variant waarin deze synthase 
tot expressie is gebracht produceert pentaleneen en ondervindt geen hinder in de 
groei door deze mutatie. Wel is deze gist wit aangezien hij geen asthaxanthine 







in de gist wanneer de vector geïntegreerd werd in de rDNA sequenties van het 
genoom, in plaats van in de twee hiervoor genoemde genen. De verkregen hoge 
concentratie kan allicht verklaard worden doordat de rDNA sequenties door het hele 
genoom verspreid zijn en de expressie cassette daardoor meerdere keren 
geïntegreerd kan zijn. 
Nadat we hebben bewezen dat onze strategie om X. dendrorhous te 
transformeren succesvol is, besloten we om de effectiviteit van de sesquiterpeen 
productie in onze gist te evalueren. In hoofdstuk 4 worden onze rode gist, E. coli én 
S. cerevisiae getransformeerd met het Cop6 gen, dat geïsoleerd is uit de 
basidiomycetes Coprinus cinereus (NL: wortelende inktzwam). Alle X. dendrorhous 
varianten produceren -cupreneen — de metaboliet geproduceerd door Cop6 — in 
hogere concentraties dan E. coli en S. cerevisiae. Dit bevestigt ons idee dat X. 
dendrorhous een grote potentie heeft voor de productie van terpenen. Verder is van 
belang dat de optimale temperatuur om onze gist te cultiveren 20 tot 24 °C is, en dat 
onze gist beter groeit in een minimaal medium dan S. cerevisiae. Deze twee feiten 
geven aan dat X. dendrorhous een goede gist kan zijn om terpenen te produceren in 
de industrie. 
Het grootste deel van de terpeen medicijnen worden geconstrueerd via 
meerdere enzymatische omzettingen in uitgebreide biosynthese routes. De resultaten 
in hoofdstuk 5 zijn verkregen door twee cytochromen — die worden gebruikt in de 
biosynthese route van lagopodine A — in combinatie met het Cop6 gen tot expressie 
te brengen in X. dendrorhous. -cupreneen is de precursor voor lagopodine A in C. 
cinereus. Door een aantal reacties kan deze precursor worden omgezet in het 
antibioticum. De genen van twee cytochromen, COX1 en COX2, zijn in de fungus 
naast het Cop6 gen gesitueerd. Aangezien genen die nodig zijn in een biosynthese 
route vaak geclusterd in het genoom te vinden zijn, zijn deze twee eiwitten 
waarschijnlijk betrokken bij de oxidatie van -cupreneen om lagopodine A te 
vormen. 
Om Cop6, COX1 én COX2 in één X. dendrorhous variant tot expressie te 
kunnen brengen, hebben we een nieuwe vector met een nieuwe expressie cassette 
ontworpen. Deze vector maakt het mogelijk om, in principe, een oneindig aantal 
kopieën van de expressie cassette — met dezelfde of alternatieve genen — tot 









brengen in X. dendrorhous, en hebben we kunnen bevestigen dat de eiwitten die 
gecodeerd worden door deze genen gebruikt worden in de biosynthese van 
lagopodine A. We hebben tussenproducten van de lagopodine A biosynthese route 
kunnen identificeren uit de X. dendrorhous mutanten, maar lagopodine A zelf kon 
niet worden geïsoleerd. Wel kon een paarse kleur worden waargenomen wanneer het 
groeimedium basisch werd gemaakt, wat aangeeft dat het antibioticum of een 
gerelateerde stof die ook paars wordt onder basische condities aanwezig is. Verder is 
het een pluspunt dat de regeneratie van de cytochromen plaatsvindt door één of 
meerdere reductases die al van nature aanwezig zijn in X. dendrorhous. Hierdoor 
hoeven er geen extra genen reductases van C. cinereus naar onze gist overgezet te 
worden. 
 
Expressie van amorphadieen synthase in cel 
compartimenten van Saccharomyces cerevisiae 
Amorphadieen synthase (ADS) is het enzym dat FPP cycliseert tot 
amorphadieen, wat op zijn beurt de precursor voor artemisinine in Artemisia annua 
is. Dit eiwit is tot expressie gebracht in verschillende organismen, bijvoorbeeld in E. 
coli, S. cerevisiae, Nicotiana tabacum and Aspergillus niger. Er is veel onderzoek 
naar de productie van artemisinine (en amorphadieen) gedaan, aangezien de 
hoeveelheid waarin dit malaria medicijn wordt geproduceerd te laag is voor de vraag. 
Door genetische modificatie van S. cerevisiae is het mogelijk om amorphadieen te 
laten produceren door deze gist. Amorphadieen kan hierna door verdere chemische 
synthese in artemisinine worden omgezet. Het ADS eiwit is in deze gist variant 
aanwezig in het cytosol van de cel. In enkele andere organismen zijn de terpeen 
precursors echter in andere cel compartimenten aanwezig, zoals in de mitochondria 
en de peroxisomen. 
In hoofdstuk 6 wordt vergeleken hoe ADS functioneert voor de productie 
van amorphadieen wanneer dit eiwit aanwezig is in óf het cytosol van S. cerevisiae, óf 
in de mitochondria óf in de peroxisomen. Hiervoor wordt gebruik gemaakt van 
speciale “targeting” sequenties, die er voor zorgen dat het ADS enzym nadat het tot 
expressie gebracht is, naar specifieke organellen wordt getransporteerd. Om te 







terecht komen, werd een fusie gemaakt van het ADS eiwit en een voor gist 
geoptimaliseerde versie van het groen fluorisceerend eiwit (EN: green fluorescent 
protein [GFP]). Fluorescentie werd door de hele cel waargenomen wanneer het niet-
specifieke ADS-GPF construct werd gebruikt, terwijl fluorescentie specifiek in de 
bewuste organellen werd waargenomen wanneer de peroxisomale of mitochrondiale 
“targeting” sequenties werden gebruikt. De gistsstam, waarin het eiwit naar de 
mitochondria getransporteerd wordt, vertoonde een veranderde groei — namelijk een 
langere aanlooptijd voordat de groei begon (de zogenaamde “lag phase”) — ten 
opzichte van de normale groei die vertoond wordt door de gist varianten met ADS in 
het cytosol of de peroxisomen. De activiteit van ADS was iets lager door de fusie met 
GFP. Amorphadieen wordt geproduceerd in alle gist varianten. Dit is een indicatie 
dat de gist FPP kan verzamelen in beide organellen. Ondanks dat de productie van 
amorphadieen in de mitochondria en peroxisomen lager is dan in het cytosol, geeft 
dit onderzoek aan dat er er meer amorphadieen in de gist cellen geproduceerd kan 
worden, aangezien er nog ongebruikte voorraden van de terpeen precursors 
beschikbaar zijn. 
 
Uit ons onderzoek blijkt dat door X. dendrorhous sesquiterpenen, die 
normaal niet gemaakt worden door deze gist, geproduceerd kunnen worden, zonder 
de groei van de gist te beïnvloeden. Het is duidelijk geworden dat, aangezien de 
metabolieten in verschillende hoeveelheden geproduceerd worden, de vorming van 
metabolieten niet afhankelijk is van de concentratie van de precursor FPP, maar dat 
de productie van metabolieten gelimiteerd wordt door de activiteit van de betrokken 
enzymen. Deze waarneming wordt bevestigd door de productie van dezelfde 
hoeveelheden pentaleneen en -cupreneen door enerzijds mutanten die nog 
astaxanthine produceren, en anderzijds “knock-out” mutanten die geen 
asthaxanthine meer kunnen vormen. De productie van tegelijkertijd asthaxanthine 
en andere sesquiterpenen geeft verder aan dat de gist een mogelijkheid heeft om nog 
grotere hoeveelheden terpeen metabolieten te produceren. Wij willen poneren dat de 
productie van sesquiterpenen in mutanten van X. dendrorhous bevorderd kan 
worden door meerdere kopieën van de betrokken genen te integreren in het genoom. 
Tijdens dit onderzoek hebben wij maar een beperkt aantal genen in X. 









makkelijk te modificeren en efficiënte vector voor de transformatie van de gist 
hebben we de tijd die nodig is om nieuwe mutanten te creëren drastisch verkort. 
Verder versnelt de mogelijkheid om een, in principe, oneindig aantal genen in één 
gist variant tot expressie te brengen de zoektocht naar het optimale terpeen-
producerend “platform organisme”. 
Er is weinig bekend over de moleculaire biologie van X. dendrorhous, en er is 
maar een klein aantal gen sequenties van deze gist geïdentificeerd. Wanneer het 
genoom van de rode gist bekend zou worden door DNA sequencing, dan zouden wij 
met deze kennis betere hulpmiddelen kunnen ontwikkelen voor ons onderzoek; 
wanneer er meer gen sequenties bekend zijn kunnen wij namelijk betrouwbaar het 
codon gebuik vaststellen, en hierdoor kan dan het codon gebruik voor heterologe 
genen geoptimaliseerd worden om een hogere translatie efficiëntie en activiteit in de 
cellen te bereiken. Verder zouden sterkere promotoren gebruikt kunnen worden om 
een betere expressie van de genen te krijgen, zodat de metabolieten met een betere 
opbrengst kunnen worden verkregen. Ook kan onderzocht worden of het mogelijk is 
om eiwitten selectief in verschillende organellen van cellen van X. dendrorhous  
terpenen te laten produceren door gebruik te maken van “targeting”, zoals we hebben 
laten zien voor ADS in S. cerevisiae. 
Verder kan door de bestudering van de metabolomen van X. dendrorhous en 
onze mutanten, de “bottlenecks” in de terpeen biosynthese route in de rode gist 
geïdentificeerd worden. Deze “bottlenecks” kunnen dan verholpen worden door 
overexpressie van die genen die coderen voor de specifieke eiwitten, wat zou leiden 
tot meer terpeen productie. 
Voor de identificatie en engineering van een organisme dat de mogelijkheid 
heeft om hoge hoeveelheden terpeen medicijnen te produceren is nog veel onderzoek 
nodig, en voor de voortgang van dit onderzoek zal de input nodig zijn van 
verschillende wetenschappelijke disciplines. Wij zijn ervan overtuigd dat we hebben 
bewezen dat X. dendrorhous een goed uitgangspunt is voor de ontwikkeling van 
nieuwe, innovatieve “platform organismen” voor de productie van terpenoïden, met 
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